The aim of this study was to compare the incidence of BRCA1 promoter region methylation in tumours in which loss of BRCA1 has been shown to play a role in pathogenesis ( breast and ovarian carcinomas) with the incidence in tumours in which BRCA1 is unlikely to play a role in pathogenesis.	"BRCA1	54	59	Gene_or_gene_product"	"tumours	91	98	Cancer"	"BRCA1	116	121	Gene_or_gene_product"	"breast	170	176	Cancer"	"ovarian carcinomas	181	199	Cancer"	"tumours	223	230	Cancer"	"BRCA1	240	245	Gene_or_gene_product"	"[{""token"": ""BRCA1"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumours"", ""start_span"": 91, ""end_span"": 98, ""type"": ""Cancer""}, {""token"": ""BRCA1"", ""start_span"": 116, ""end_span"": 121, ""type"": ""Gene_or_gene_product""}, {""token"": ""breast"", ""start_span"": 170, ""end_span"": 176, ""type"": ""Cancer""}, {""token"": ""ovarian carcinomas"", ""start_span"": 181, ""end_span"": 199, ""type"": ""Cancer""}, {""token"": ""tumours"", ""start_span"": 223, ""end_span"": 230, ""type"": ""Cancer""}, {""token"": ""BRCA1"", ""start_span"": 240, ""end_span"": 245, ""type"": ""Gene_or_gene_product""}]"
Promoter region hypermethylation was significantly more common ( P < 0. 008) in breast and ovarian cancer ( 6 / 38 tumours methylated) than in colon cancer ( 0 / 35 tumours methylated) or in leukaemias ( 0 / 19 samples methylated).	"breast	80	86	Cancer"	"ovarian cancer	91	105	Cancer"	"tumours	115	122	Cancer"	"colon cancer	143	155	Cancer"	"tumours	165	172	Cancer"	"leukaemias	191	201	Cancer"	"samples	211	218	Cancer"	"[{""token"": ""breast"", ""start_span"": 80, ""end_span"": 86, ""type"": ""Cancer""}, {""token"": ""ovarian cancer"", ""start_span"": 91, ""end_span"": 105, ""type"": ""Cancer""}, {""token"": ""tumours"", ""start_span"": 115, ""end_span"": 122, ""type"": ""Cancer""}, {""token"": ""colon cancer"", ""start_span"": 143, ""end_span"": 155, ""type"": ""Cancer""}, {""token"": ""tumours"", ""start_span"": 165, ""end_span"": 172, ""type"": ""Cancer""}, {""token"": ""leukaemias"", ""start_span"": 191, ""end_span"": 201, ""type"": ""Cancer""}, {""token"": ""samples"", ""start_span"": 211, ""end_span"": 218, ""type"": ""Cancer""}]"
The nm23 - H1 mRNA expression levels in CBM with lymph nodes metastases were lower than those in CBM without metastases ( P < 0. 05), while no significance of nm23 - H2 mRNA expression levels was found between CBM with and CBM without metastasis ( P > 0. 05).	"nm23 - H1	4	13	Gene_or_gene_product"	"CBM	40	43	Cancer"	"lymph nodes	49	60	Multi"	"CBM	97	100	Cancer"	"nm23 - H2	159	168	Gene_or_gene_product"	"CBM	210	213	Cancer"	"CBM	223	226	Cancer"	"[{""token"": ""nm23 - H1"", ""start_span"": 4, ""end_span"": 13, ""type"": ""Gene_or_gene_product""}, {""token"": ""CBM"", ""start_span"": 40, ""end_span"": 43, ""type"": ""Cancer""}, {""token"": ""lymph nodes"", ""start_span"": 49, ""end_span"": 60, ""type"": ""Multi""}, {""token"": ""CBM"", ""start_span"": 97, ""end_span"": 100, ""type"": ""Cancer""}, {""token"": ""nm23 - H2"", ""start_span"": 159, ""end_span"": 168, ""type"": ""Gene_or_gene_product""}, {""token"": ""CBM"", ""start_span"": 210, ""end_span"": 213, ""type"": ""Cancer""}, {""token"": ""CBM"", ""start_span"": 223, ""end_span"": 226, ""type"": ""Cancer""}]"
In the current article we demonstrate that TnI inhibits both bFGF - stimulated and basal levels of endothelial cell proliferation, and we hypothesize that this inhibition is occurring, at least in part, via an interaction of TnI with the cell - surface bFGF receptor on capillary endothelial cells.	"TnI	43	46	Gene_or_gene_product"	"bFGF	61	65	Gene_or_gene_product"	"endothelial cell	99	115	Cell"	"TnI	225	228	Gene_or_gene_product"	"cell - surface	238	252	Cellular_component"	"bFGF receptor	253	266	Gene_or_gene_product"	"capillary endothelial cells	270	297	Cell"	"[{""token"": ""TnI"", ""start_span"": 43, ""end_span"": 46, ""type"": ""Gene_or_gene_product""}, {""token"": ""bFGF"", ""start_span"": 61, ""end_span"": 65, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial cell"", ""start_span"": 99, ""end_span"": 115, ""type"": ""Cell""}, {""token"": ""TnI"", ""start_span"": 225, ""end_span"": 228, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell - surface"", ""start_span"": 238, ""end_span"": 252, ""type"": ""Cellular_component""}, {""token"": ""bFGF receptor"", ""start_span"": 253, ""end_span"": 266, ""type"": ""Gene_or_gene_product""}, {""token"": ""capillary endothelial cells"", ""start_span"": 270, ""end_span"": 297, ""type"": ""Cell""}]"
Notably, three immortalizing E6 mutants that do not induce direct p53 degradation but do interact with hADA3 induced the abrogation of p53 - mediated transactivation and G ( 1) cell cycle arrest after DNA damage, comparable to wild - type E6.	"E6	29	31	Gene_or_gene_product"	"p53	66	69	Gene_or_gene_product"	"hADA3	103	108	Gene_or_gene_product"	"p53	135	138	Gene_or_gene_product"	"cell	177	181	Cell"	"DNA	201	204	Cellular_component"	"E6	239	241	Gene_or_gene_product"	"[{""token"": ""E6"", ""start_span"": 29, ""end_span"": 31, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Gene_or_gene_product""}, {""token"": ""hADA3"", ""start_span"": 103, ""end_span"": 108, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Cell""}, {""token"": ""DNA"", ""start_span"": 201, ""end_span"": 204, ""type"": ""Cellular_component""}, {""token"": ""E6"", ""start_span"": 239, ""end_span"": 241, ""type"": ""Gene_or_gene_product""}]"
317615 x 2HCl was an active antitumor agent against the MX - 1 xenograft and increased the tumor growth delay produced by paclitaxel by 1. 7 - fold and the tumor growth delay produced by carboplatin by 3. 8 - fold.	"317615 x 2HCl	0	13	Chemical"	"antitumor	28	37	Cancer"	"MX - 1 xenograft	56	72	Cancer"	"tumor	91	96	Cancer"	"paclitaxel	122	132	Chemical"	"tumor	156	161	Cancer"	"carboplatin	187	198	Chemical"	"[{""token"": ""317615 x 2HCl"", ""start_span"": 0, ""end_span"": 13, ""type"": ""Chemical""}, {""token"": ""antitumor"", ""start_span"": 28, ""end_span"": 37, ""type"": ""Cancer""}, {""token"": ""MX - 1 xenograft"", ""start_span"": 56, ""end_span"": 72, ""type"": ""Cancer""}, {""token"": ""tumor"", ""start_span"": 91, ""end_span"": 96, ""type"": ""Cancer""}, {""token"": ""paclitaxel"", ""start_span"": 122, ""end_span"": 132, ""type"": ""Chemical""}, {""token"": ""tumor"", ""start_span"": 156, ""end_span"": 161, ""type"": ""Cancer""}, {""token"": ""carboplatin"", ""start_span"": 187, ""end_span"": 198, ""type"": ""Chemical""}]"
Blockade of PAF - R by WEB - 2170, a PAF - R antagonist, abolished the CD154 - dependent motility, indicating a role for PAF synthesized after CD154 stimulation in renal carcinoma cell motility.	"PAF - R	12	19	Gene_or_gene_product"	"WEB - 2170	23	33	Chemical"	"PAF - R	37	44	Gene_or_gene_product"	"CD154	71	76	Gene_or_gene_product"	"PAF	121	124	Chemical"	"CD154	143	148	Gene_or_gene_product"	"renal carcinoma cell	164	184	Cell"	"[{""token"": ""PAF - R"", ""start_span"": 12, ""end_span"": 19, ""type"": ""Gene_or_gene_product""}, {""token"": ""WEB - 2170"", ""start_span"": 23, ""end_span"": 33, ""type"": ""Chemical""}, {""token"": ""PAF - R"", ""start_span"": 37, ""end_span"": 44, ""type"": ""Gene_or_gene_product""}, {""token"": ""CD154"", ""start_span"": 71, ""end_span"": 76, ""type"": ""Gene_or_gene_product""}, {""token"": ""PAF"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Chemical""}, {""token"": ""CD154"", ""start_span"": 143, ""end_span"": 148, ""type"": ""Gene_or_gene_product""}, {""token"": ""renal carcinoma cell"", ""start_span"": 164, ""end_span"": 184, ""type"": ""Cell""}]"
Here we report that the chemotherapeutic drug doxorubicin, a DNA - damaging agent, activates a p53 - survivin signaling pathway inducing cell cycle arrest and apoptosis in childhood acute lymphoblastic leukemia ( ALL).	"doxorubicin	46	57	Chemical"	"DNA	61	64	Cellular_component"	"p53	95	98	Gene_or_gene_product"	"survivin	101	109	Gene_or_gene_product"	"cell	137	141	Cell"	"acute lymphoblastic leukemia	182	210	Cancer"	"ALL	213	216	Cancer"	"[{""token"": ""doxorubicin"", ""start_span"": 46, ""end_span"": 57, ""type"": ""Chemical""}, {""token"": ""DNA"", ""start_span"": 61, ""end_span"": 64, ""type"": ""Cellular_component""}, {""token"": ""p53"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Gene_or_gene_product""}, {""token"": ""survivin"", ""start_span"": 101, ""end_span"": 109, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 137, ""end_span"": 141, ""type"": ""Cell""}, {""token"": ""acute lymphoblastic leukemia"", ""start_span"": 182, ""end_span"": 210, ""type"": ""Cancer""}, {""token"": ""ALL"", ""start_span"": 213, ""end_span"": 216, ""type"": ""Cancer""}]"
A vascular permeability enhancement ( VPE) assay was performed using guinea pigs to ascertain whether supernatant from cultures of Ve - and OMP - stimulated HGF enhance vascular permeability in vivo.	"vascular	2	10	Multi"	"guinea pigs	69	80	Organism"	"supernatant	102	113	Organism_substance"	"Ve	131	133	Gene_or_gene_product"	"OMP	140	143	Gene_or_gene_product"	"HGF	157	160	Cell"	"vascular	169	177	Multi"	"[{""token"": ""vascular"", ""start_span"": 2, ""end_span"": 10, ""type"": ""Multi""}, {""token"": ""guinea pigs"", ""start_span"": 69, ""end_span"": 80, ""type"": ""Organism""}, {""token"": ""supernatant"", ""start_span"": 102, ""end_span"": 113, ""type"": ""Organism_substance""}, {""token"": ""Ve"", ""start_span"": 131, ""end_span"": 133, ""type"": ""Gene_or_gene_product""}, {""token"": ""OMP"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Gene_or_gene_product""}, {""token"": ""HGF"", ""start_span"": 157, ""end_span"": 160, ""type"": ""Cell""}, {""token"": ""vascular"", ""start_span"": 169, ""end_span"": 177, ""type"": ""Multi""}]"
BX471 ( R - N - [ 5 - chloro - 2 - [ 2 - [ 4 ( 4 - fluorophenyl) methyl] - 2 - methyl - 1 - piperazinyl] - 2 - oxoethoxy] phenyl] urea hydrochloric acid salt), a CCR1 antagonist, inhibits angiogenic properties of CCL16, whereas blocking of CCR8 or desensitizing CCR2, which are both well known receptors for CCL16, did not abolish endothelial activation.	"BX471	0	5	Chemical"	"CCR1	162	166	Gene_or_gene_product"	"CCL16	213	218	Gene_or_gene_product"	"CCR8	240	244	Gene_or_gene_product"	"CCR2	262	266	Gene_or_gene_product"	"CCL16	308	313	Gene_or_gene_product"	"endothelial	331	342	Cell"	"[{""token"": ""BX471"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Chemical""}, {""token"": ""CCR1"", ""start_span"": 162, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}, {""token"": ""CCL16"", ""start_span"": 213, ""end_span"": 218, ""type"": ""Gene_or_gene_product""}, {""token"": ""CCR8"", ""start_span"": 240, ""end_span"": 244, ""type"": ""Gene_or_gene_product""}, {""token"": ""CCR2"", ""start_span"": 262, ""end_span"": 266, ""type"": ""Gene_or_gene_product""}, {""token"": ""CCL16"", ""start_span"": 308, ""end_span"": 313, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial"", ""start_span"": 331, ""end_span"": 342, ""type"": ""Cell""}]"
Analysis of gene expression revealed increased expression of ANGPT1, ANGPT2, platelet - derived growth factor - B, placental growth factor, and VEGF mRNA in AdCA5 - injected eyes.	"ANGPT1	61	67	Gene_or_gene_product"	"ANGPT2	69	75	Gene_or_gene_product"	"platelet - derived growth factor - B	77	113	Gene_or_gene_product"	"placental growth factor	115	138	Gene_or_gene_product"	"VEGF	144	148	Gene_or_gene_product"	"AdCA5	157	162	Organism"	"eyes	174	178	Organ"	"[{""token"": ""ANGPT1"", ""start_span"": 61, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""ANGPT2"", ""start_span"": 69, ""end_span"": 75, ""type"": ""Gene_or_gene_product""}, {""token"": ""platelet - derived growth factor - B"", ""start_span"": 77, ""end_span"": 113, ""type"": ""Gene_or_gene_product""}, {""token"": ""placental growth factor"", ""start_span"": 115, ""end_span"": 138, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 144, ""end_span"": 148, ""type"": ""Gene_or_gene_product""}, {""token"": ""AdCA5"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Organism""}, {""token"": ""eyes"", ""start_span"": 174, ""end_span"": 178, ""type"": ""Organ""}]"
In conclusion, our study revealed that the overexpression of EphA2 protein in colorectal carcinoma tissue correlates closely with cancer progression and hematogenous and lymphogenous metastasis, suggesting that both EphA2 and E - cadherin may play an important role in tumor metastasis in colorectal cancer.	"EphA2	61	66	Gene_or_gene_product"	"colorectal carcinoma tissue	78	105	Tissue"	"cancer	130	136	Cancer"	"EphA2	216	221	Gene_or_gene_product"	"E - cadherin	226	238	Gene_or_gene_product"	"tumor	269	274	Cancer"	"colorectal cancer	289	306	Cancer"	"[{""token"": ""EphA2"", ""start_span"": 61, ""end_span"": 66, ""type"": ""Gene_or_gene_product""}, {""token"": ""colorectal carcinoma tissue"", ""start_span"": 78, ""end_span"": 105, ""type"": ""Tissue""}, {""token"": ""cancer"", ""start_span"": 130, ""end_span"": 136, ""type"": ""Cancer""}, {""token"": ""EphA2"", ""start_span"": 216, ""end_span"": 221, ""type"": ""Gene_or_gene_product""}, {""token"": ""E - cadherin"", ""start_span"": 226, ""end_span"": 238, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor"", ""start_span"": 269, ""end_span"": 274, ""type"": ""Cancer""}, {""token"": ""colorectal cancer"", ""start_span"": 289, ""end_span"": 306, ""type"": ""Cancer""}]"
Clusterin expression level depends on cell proliferation state, and we recently showed that its over - expression inhibited cell cycle progression of SV40 - immortalized human prostate epithelial cells PNT2 and PNT1a.	"Clusterin	0	9	Gene_or_gene_product"	"cell	38	42	Cell"	"cell	124	128	Cell"	"SV40	150	154	Organism"	"human	170	175	Organism"	"prostate epithelial cells PNT2	176	206	Cell"	"PNT1a	211	216	Cell"	"[{""token"": ""Clusterin"", ""start_span"": 0, ""end_span"": 9, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Cell""}, {""token"": ""cell"", ""start_span"": 124, ""end_span"": 128, ""type"": ""Cell""}, {""token"": ""SV40"", ""start_span"": 150, ""end_span"": 154, ""type"": ""Organism""}, {""token"": ""human"", ""start_span"": 170, ""end_span"": 175, ""type"": ""Organism""}, {""token"": ""prostate epithelial cells PNT2"", ""start_span"": 176, ""end_span"": 206, ""type"": ""Cell""}, {""token"": ""PNT1a"", ""start_span"": 211, ""end_span"": 216, ""type"": ""Cell""}]"
We quantified CYR61, CTGF, WISP - 1, and NOV mRNA expression levels in samples from sixty - six primary gliomas and five normal brain samples using quantitative real - time PCR assay.	"CYR61	14	19	Gene_or_gene_product"	"CTGF	21	25	Gene_or_gene_product"	"WISP - 1	27	35	Gene_or_gene_product"	"NOV	41	44	Gene_or_gene_product"	"samples	71	78	Cancer"	"gliomas	104	111	Cancer"	"brain samples	128	141	Multi"	"[{""token"": ""CYR61"", ""start_span"": 14, ""end_span"": 19, ""type"": ""Gene_or_gene_product""}, {""token"": ""CTGF"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Gene_or_gene_product""}, {""token"": ""WISP - 1"", ""start_span"": 27, ""end_span"": 35, ""type"": ""Gene_or_gene_product""}, {""token"": ""NOV"", ""start_span"": 41, ""end_span"": 44, ""type"": ""Gene_or_gene_product""}, {""token"": ""samples"", ""start_span"": 71, ""end_span"": 78, ""type"": ""Cancer""}, {""token"": ""gliomas"", ""start_span"": 104, ""end_span"": 111, ""type"": ""Cancer""}, {""token"": ""brain samples"", ""start_span"": 128, ""end_span"": 141, ""type"": ""Multi""}]"
The aim of this study is to investigate ( 1) whether expression of COX - 2 and PPARgamma is associated with ovarian carcinogenesis and progression of ovarian tumours and ( 2) whether COX - 2 expression is controlled through ligand - mediated activation of PPARgamma in ovarian carcinoma cells.	"COX - 2	67	74	Gene_or_gene_product"	"PPARgamma	79	88	Gene_or_gene_product"	"ovarian	108	115	Organ"	"ovarian tumours	150	165	Cancer"	"COX - 2	183	190	Gene_or_gene_product"	"PPARgamma	256	265	Gene_or_gene_product"	"ovarian carcinoma cells	269	292	Cell"	"[{""token"": ""COX - 2"", ""start_span"": 67, ""end_span"": 74, ""type"": ""Gene_or_gene_product""}, {""token"": ""PPARgamma"", ""start_span"": 79, ""end_span"": 88, ""type"": ""Gene_or_gene_product""}, {""token"": ""ovarian"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Organ""}, {""token"": ""ovarian tumours"", ""start_span"": 150, ""end_span"": 165, ""type"": ""Cancer""}, {""token"": ""COX - 2"", ""start_span"": 183, ""end_span"": 190, ""type"": ""Gene_or_gene_product""}, {""token"": ""PPARgamma"", ""start_span"": 256, ""end_span"": 265, ""type"": ""Gene_or_gene_product""}, {""token"": ""ovarian carcinoma cells"", ""start_span"": 269, ""end_span"": 292, ""type"": ""Cell""}]"
From these results, it was suggested that PPARgamma activation might suppress COX - 2 expression via the nuclear factor - kappaB pathway in the ovarian carcinoma cells and that low expression of PPARgamma and high expression of COX - 2 might be involved in carcinogenesis and progression of ovarian tumours.	"PPARgamma	42	51	Gene_or_gene_product"	"COX - 2	78	85	Gene_or_gene_product"	"nuclear factor - kappaB	105	128	Gene_or_gene_product"	"ovarian carcinoma cells	144	167	Cell"	"PPARgamma	195	204	Gene_or_gene_product"	"COX - 2	228	235	Gene_or_gene_product"	"ovarian tumours	291	306	Cancer"	"[{""token"": ""PPARgamma"", ""start_span"": 42, ""end_span"": 51, ""type"": ""Gene_or_gene_product""}, {""token"": ""COX - 2"", ""start_span"": 78, ""end_span"": 85, ""type"": ""Gene_or_gene_product""}, {""token"": ""nuclear factor - kappaB"", ""start_span"": 105, ""end_span"": 128, ""type"": ""Gene_or_gene_product""}, {""token"": ""ovarian carcinoma cells"", ""start_span"": 144, ""end_span"": 167, ""type"": ""Cell""}, {""token"": ""PPARgamma"", ""start_span"": 195, ""end_span"": 204, ""type"": ""Gene_or_gene_product""}, {""token"": ""COX - 2"", ""start_span"": 228, ""end_span"": 235, ""type"": ""Gene_or_gene_product""}, {""token"": ""ovarian tumours"", ""start_span"": 291, ""end_span"": 306, ""type"": ""Cancer""}]"
The Kaposi ' s sarcoma - associated herpesvirus ( KSHV) encodes a G protein - coupled receptor ( vGPCR) that has been implicated in the initiation of Kaposi ' s sarcoma, identifying vGPCR as an attractive target for preventing Kaposi ' s sarcoma.	"Kaposi ' s sarcoma - associated herpesvirus	4	47	Organism"	"KSHV	50	54	Organism"	"G protein - coupled receptor	66	94	Gene_or_gene_product"	"vGPCR	97	102	Gene_or_gene_product"	"Kaposi ' s sarcoma	150	168	Cancer"	"vGPCR	182	187	Gene_or_gene_product"	"Kaposi ' s sarcoma	227	245	Cancer"	"[{""token"": ""Kaposi ' s sarcoma - associated herpesvirus"", ""start_span"": 4, ""end_span"": 47, ""type"": ""Organism""}, {""token"": ""KSHV"", ""start_span"": 50, ""end_span"": 54, ""type"": ""Organism""}, {""token"": ""G protein - coupled receptor"", ""start_span"": 66, ""end_span"": 94, ""type"": ""Gene_or_gene_product""}, {""token"": ""vGPCR"", ""start_span"": 97, ""end_span"": 102, ""type"": ""Gene_or_gene_product""}, {""token"": ""Kaposi ' s sarcoma"", ""start_span"": 150, ""end_span"": 168, ""type"": ""Cancer""}, {""token"": ""vGPCR"", ""start_span"": 182, ""end_span"": 187, ""type"": ""Gene_or_gene_product""}, {""token"": ""Kaposi ' s sarcoma"", ""start_span"": 227, ""end_span"": 245, ""type"": ""Cancer""}]"
Recent reports suggest a participation of matrix metalloproteinases ( MMP) in tumour pericyte recruitment that is consistent with the effect of certain MMPs in the development of microvasculature in embryonic development and in in vitro models of vascular remodelling.	"matrix metalloproteinases	42	67	Gene_or_gene_product"	"MMP	70	73	Gene_or_gene_product"	"tumour pericyte	78	93	Cell"	"MMPs	152	156	Gene_or_gene_product"	"microvasculature	179	195	Tissue"	"embryonic	199	208	Developing_anatomical_structure"	"vascular	247	255	Multi"	"[{""token"": ""matrix metalloproteinases"", ""start_span"": 42, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""MMP"", ""start_span"": 70, ""end_span"": 73, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumour pericyte"", ""start_span"": 78, ""end_span"": 93, ""type"": ""Cell""}, {""token"": ""MMPs"", ""start_span"": 152, ""end_span"": 156, ""type"": ""Gene_or_gene_product""}, {""token"": ""microvasculature"", ""start_span"": 179, ""end_span"": 195, ""type"": ""Tissue""}, {""token"": ""embryonic"", ""start_span"": 199, ""end_span"": 208, ""type"": ""Developing_anatomical_structure""}, {""token"": ""vascular"", ""start_span"": 247, ""end_span"": 255, ""type"": ""Multi""}]"
This was confirmed with chromatin immunoprecipitation experiments of the human c - Met promoter, as well as by the ability of adenovirally expressed Mitf to modulate endogenous c - Met protein levels in melanocytes.	"chromatin	24	33	Cellular_component"	"human	73	78	Organism"	"c - Met	79	86	Gene_or_gene_product"	"adenovirally	126	138	Organism"	"Mitf	149	153	Gene_or_gene_product"	"c - Met	177	184	Gene_or_gene_product"	"melanocytes	203	214	Cell"	"[{""token"": ""chromatin"", ""start_span"": 24, ""end_span"": 33, ""type"": ""Cellular_component""}, {""token"": ""human"", ""start_span"": 73, ""end_span"": 78, ""type"": ""Organism""}, {""token"": ""c - Met"", ""start_span"": 79, ""end_span"": 86, ""type"": ""Gene_or_gene_product""}, {""token"": ""adenovirally"", ""start_span"": 126, ""end_span"": 138, ""type"": ""Organism""}, {""token"": ""Mitf"", ""start_span"": 149, ""end_span"": 153, ""type"": ""Gene_or_gene_product""}, {""token"": ""c - Met"", ""start_span"": 177, ""end_span"": 184, ""type"": ""Gene_or_gene_product""}, {""token"": ""melanocytes"", ""start_span"": 203, ""end_span"": 214, ""type"": ""Cell""}]"
Finally, dominant - negative inhibition of Mitf resulted in profound resistance of melanocytes and melanoma cells to HGF - dependent matrix invasion, suggesting a physiologic role for this pathway in melanocytic development and melanoma.	"Mitf	43	47	Gene_or_gene_product"	"melanocytes	83	94	Cell"	"melanoma cells	99	113	Cell"	"HGF	117	120	Gene_or_gene_product"	"matrix	133	139	Cellular_component"	"melanocytic	200	211	Cell"	"melanoma	228	236	Cancer"	"[{""token"": ""Mitf"", ""start_span"": 43, ""end_span"": 47, ""type"": ""Gene_or_gene_product""}, {""token"": ""melanocytes"", ""start_span"": 83, ""end_span"": 94, ""type"": ""Cell""}, {""token"": ""melanoma cells"", ""start_span"": 99, ""end_span"": 113, ""type"": ""Cell""}, {""token"": ""HGF"", ""start_span"": 117, ""end_span"": 120, ""type"": ""Gene_or_gene_product""}, {""token"": ""matrix"", ""start_span"": 133, ""end_span"": 139, ""type"": ""Cellular_component""}, {""token"": ""melanocytic"", ""start_span"": 200, ""end_span"": 211, ""type"": ""Cell""}, {""token"": ""melanoma"", ""start_span"": 228, ""end_span"": 236, ""type"": ""Cancer""}]"
Targeted down - regulation of PIM - 2 by RNA interference ( RNAi) selectively abrogated survival of Ba / F3 cells transformed by various Fms - like tyrosine kinase 3 ( FLT3) - activating mutants [ internal tandem duplication ( ITD) and kinase domain] and attenuated growth of human cell lines containing FLT3 mutations.	"PIM - 2	30	37	Gene_or_gene_product"	"Ba / F3 cells	100	113	Cell"	"Fms - like tyrosine kinase 3	137	165	Gene_or_gene_product"	"FLT3	168	172	Gene_or_gene_product"	"human	276	281	Organism"	"cell lines	282	292	Cell"	"FLT3	304	308	Gene_or_gene_product"	"[{""token"": ""PIM - 2"", ""start_span"": 30, ""end_span"": 37, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ba / F3 cells"", ""start_span"": 100, ""end_span"": 113, ""type"": ""Cell""}, {""token"": ""Fms - like tyrosine kinase 3"", ""start_span"": 137, ""end_span"": 165, ""type"": ""Gene_or_gene_product""}, {""token"": ""FLT3"", ""start_span"": 168, ""end_span"": 172, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 276, ""end_span"": 281, ""type"": ""Organism""}, {""token"": ""cell lines"", ""start_span"": 282, ""end_span"": 292, ""type"": ""Cell""}, {""token"": ""FLT3"", ""start_span"": 304, ""end_span"": 308, ""type"": ""Gene_or_gene_product""}]"
Endothelial cells grown at normal pH suffer no ill effects from this angiostatin - mediated inhibition of ATP synthase, whereas endothelial cells grown at low, tumor - like extracellular pH cannot maintain a normal intracellular pH and die.	"Endothelial cells	0	17	Cell"	"angiostatin	69	80	Gene_or_gene_product"	"ATP synthase	106	118	Gene_or_gene_product"	"endothelial cells	128	145	Cell"	"tumor	160	165	Cancer"	"extracellular	173	186	Immaterial_anatomical_entity"	"intracellular	215	228	Immaterial_anatomical_entity"	"[{""token"": ""Endothelial cells"", ""start_span"": 0, ""end_span"": 17, ""type"": ""Cell""}, {""token"": ""angiostatin"", ""start_span"": 69, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""ATP synthase"", ""start_span"": 106, ""end_span"": 118, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial cells"", ""start_span"": 128, ""end_span"": 145, ""type"": ""Cell""}, {""token"": ""tumor"", ""start_span"": 160, ""end_span"": 165, ""type"": ""Cancer""}, {""token"": ""extracellular"", ""start_span"": 173, ""end_span"": 186, ""type"": ""Immaterial_anatomical_entity""}, {""token"": ""intracellular"", ""start_span"": 215, ""end_span"": 228, ""type"": ""Immaterial_anatomical_entity""}]"
In the present study a DNA probe derived from cellular DNA sequences adjacent to the previously characterized HBV insert was used to analyze a set of 19 matched normal liver and HBV - positive hepatoma samples obtained from the same region of China, near Shanghai.	"DNA	23	26	Cellular_component"	"cellular	46	54	Cell"	"DNA	55	58	Cellular_component"	"HBV	110	113	Organism"	"liver	168	173	Organ"	"HBV	178	181	Organism"	"hepatoma samples	193	209	Tissue"	"[{""token"": ""DNA"", ""start_span"": 23, ""end_span"": 26, ""type"": ""Cellular_component""}, {""token"": ""cellular"", ""start_span"": 46, ""end_span"": 54, ""type"": ""Cell""}, {""token"": ""DNA"", ""start_span"": 55, ""end_span"": 58, ""type"": ""Cellular_component""}, {""token"": ""HBV"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Organism""}, {""token"": ""liver"", ""start_span"": 168, ""end_span"": 173, ""type"": ""Organ""}, {""token"": ""HBV"", ""start_span"": 178, ""end_span"": 181, ""type"": ""Organism""}, {""token"": ""hepatoma samples"", ""start_span"": 193, ""end_span"": 209, ""type"": ""Tissue""}]"
Tumor - specific DNA changes were detected in two additional HCCs, suggesting that the small region of chromosome 17p defined by the flanking cell DNA probe is commonly altered in hepatomas.	"Tumor	0	5	Cancer"	"DNA	17	20	Cellular_component"	"HCCs	61	65	Cancer"	"chromosome 17p	103	117	Cellular_component"	"cell	142	146	Cell"	"DNA	147	150	Cellular_component"	"hepatomas	180	189	Cancer"	"[{""token"": ""Tumor"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Cancer""}, {""token"": ""DNA"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Cellular_component""}, {""token"": ""HCCs"", ""start_span"": 61, ""end_span"": 65, ""type"": ""Cancer""}, {""token"": ""chromosome 17p"", ""start_span"": 103, ""end_span"": 117, ""type"": ""Cellular_component""}, {""token"": ""cell"", ""start_span"": 142, ""end_span"": 146, ""type"": ""Cell""}, {""token"": ""DNA"", ""start_span"": 147, ""end_span"": 150, ""type"": ""Cellular_component""}, {""token"": ""hepatomas"", ""start_span"": 180, ""end_span"": 189, ""type"": ""Cancer""}]"
This negative regulation is mediated by the cytoskeleton as the disruption of interactions between the PSMA cytoplasmic tail and the anchor protein filamin A decreases PSMA activity, integrin function, and PAK activation.	"cytoskeleton	44	56	Cellular_component"	"PSMA	103	107	Gene_or_gene_product"	"cytoplasmic	108	119	Organism_substance"	"filamin A	148	157	Gene_or_gene_product"	"PSMA	168	172	Gene_or_gene_product"	"integrin	183	191	Gene_or_gene_product"	"PAK	206	209	Gene_or_gene_product"	"[{""token"": ""cytoskeleton"", ""start_span"": 44, ""end_span"": 56, ""type"": ""Cellular_component""}, {""token"": ""PSMA"", ""start_span"": 103, ""end_span"": 107, ""type"": ""Gene_or_gene_product""}, {""token"": ""cytoplasmic"", ""start_span"": 108, ""end_span"": 119, ""type"": ""Organism_substance""}, {""token"": ""filamin A"", ""start_span"": 148, ""end_span"": 157, ""type"": ""Gene_or_gene_product""}, {""token"": ""PSMA"", ""start_span"": 168, ""end_span"": 172, ""type"": ""Gene_or_gene_product""}, {""token"": ""integrin"", ""start_span"": 183, ""end_span"": 191, ""type"": ""Gene_or_gene_product""}, {""token"": ""PAK"", ""start_span"": 206, ""end_span"": 209, ""type"": ""Gene_or_gene_product""}]"
In vivo animal models of tissue injury and in vitro data also implicate syndecans in processes necessary for wound healing, including fibroblast and endothelial proliferation, cell motility, angiogenesis, and extracellular matrix organization.	"tissue	25	31	Tissue"	"syndecans	72	81	Gene_or_gene_product"	"wound	109	114	Pathological_formation"	"fibroblast	134	144	Cell"	"endothelial	149	160	Cell"	"cell	176	180	Cell"	"extracellular matrix	209	229	Cellular_component"	"[{""token"": ""tissue"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Tissue""}, {""token"": ""syndecans"", ""start_span"": 72, ""end_span"": 81, ""type"": ""Gene_or_gene_product""}, {""token"": ""wound"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Pathological_formation""}, {""token"": ""fibroblast"", ""start_span"": 134, ""end_span"": 144, ""type"": ""Cell""}, {""token"": ""endothelial"", ""start_span"": 149, ""end_span"": 160, ""type"": ""Cell""}, {""token"": ""cell"", ""start_span"": 176, ""end_span"": 180, ""type"": ""Cell""}, {""token"": ""extracellular matrix"", ""start_span"": 209, ""end_span"": 229, ""type"": ""Cellular_component""}]"
In this work, we show that LPA stimulates invasion of primary ovarian cancer cells, but not ovarian epithelial or borderline ovarian tumor cells, although these benign cells indeed respond to LPA in cell migration.	"LPA	27	30	Chemical"	"ovarian cancer cells	62	82	Cell"	"ovarian epithelial	92	110	Cell"	"borderline ovarian tumor cells	114	144	Cell"	"benign cells	161	173	Cell"	"LPA	192	195	Chemical"	"cell	199	203	Cell"	"[{""token"": ""LPA"", ""start_span"": 27, ""end_span"": 30, ""type"": ""Chemical""}, {""token"": ""ovarian cancer cells"", ""start_span"": 62, ""end_span"": 82, ""type"": ""Cell""}, {""token"": ""ovarian epithelial"", ""start_span"": 92, ""end_span"": 110, ""type"": ""Cell""}, {""token"": ""borderline ovarian tumor cells"", ""start_span"": 114, ""end_span"": 144, ""type"": ""Cell""}, {""token"": ""benign cells"", ""start_span"": 161, ""end_span"": 173, ""type"": ""Cell""}, {""token"": ""LPA"", ""start_span"": 192, ""end_span"": 195, ""type"": ""Chemical""}, {""token"": ""cell"", ""start_span"": 199, ""end_span"": 203, ""type"": ""Cell""}]"
MATERIALS AND METHODS: Forty - two MRI exams were performed with intravascular contrast media in 21 rats: tumours were induced by subcutaneous injection of colon carcinoma cells in 7 rats and mammary adenocarcinoma cells in 14 rats.	"intravascular	65	78	Immaterial_anatomical_entity"	"rats	100	104	Organism"	"tumours	106	113	Cancer"	"colon carcinoma cells	156	177	Cell"	"rats	183	187	Organism"	"mammary adenocarcinoma cells	192	220	Cell"	"rats	227	231	Organism"	"[{""token"": ""intravascular"", ""start_span"": 65, ""end_span"": 78, ""type"": ""Immaterial_anatomical_entity""}, {""token"": ""rats"", ""start_span"": 100, ""end_span"": 104, ""type"": ""Organism""}, {""token"": ""tumours"", ""start_span"": 106, ""end_span"": 113, ""type"": ""Cancer""}, {""token"": ""colon carcinoma cells"", ""start_span"": 156, ""end_span"": 177, ""type"": ""Cell""}, {""token"": ""rats"", ""start_span"": 183, ""end_span"": 187, ""type"": ""Organism""}, {""token"": ""mammary adenocarcinoma cells"", ""start_span"": 192, ""end_span"": 220, ""type"": ""Cell""}, {""token"": ""rats"", ""start_span"": 227, ""end_span"": 231, ""type"": ""Organism""}]"
A panel of antibodies was used for immunohistochemistry: CD34 / Ki - 67, carbonic anhydrase IX, hypoxia - inducible factor - 1alpha ( HIF - 1alpha) and vascular endothelial growth factor ( VEGF).	"CD34	57	61	Gene_or_gene_product"	"Ki - 67	64	71	Gene_or_gene_product"	"carbonic anhydrase IX	73	94	Gene_or_gene_product"	"hypoxia - inducible factor - 1alpha	96	131	Gene_or_gene_product"	"HIF - 1alpha	134	146	Gene_or_gene_product"	"vascular endothelial growth factor	152	186	Gene_or_gene_product"	"VEGF	189	193	Gene_or_gene_product"	"[{""token"": ""CD34"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ki - 67"", ""start_span"": 64, ""end_span"": 71, ""type"": ""Gene_or_gene_product""}, {""token"": ""carbonic anhydrase IX"", ""start_span"": 73, ""end_span"": 94, ""type"": ""Gene_or_gene_product""}, {""token"": ""hypoxia - inducible factor - 1alpha"", ""start_span"": 96, ""end_span"": 131, ""type"": ""Gene_or_gene_product""}, {""token"": ""HIF - 1alpha"", ""start_span"": 134, ""end_span"": 146, ""type"": ""Gene_or_gene_product""}, {""token"": ""vascular endothelial growth factor"", ""start_span"": 152, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF"", ""start_span"": 189, ""end_span"": 193, ""type"": ""Gene_or_gene_product""}]"
In 1986, Dvorak went on to demonstrate that VPF was secreted by a variety of human tumor cell lines and proposed that VPF was in part responsible for the abnormal vasculature seen in human tumors.	"VPF	44	47	Gene_or_gene_product"	"human	77	82	Organism"	"tumor cell lines	83	99	Cell"	"VPF	118	121	Gene_or_gene_product"	"vasculature	163	174	Multi"	"human	183	188	Organism"	"tumors	189	195	Cancer"	"[{""token"": ""VPF"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Organism""}, {""token"": ""tumor cell lines"", ""start_span"": 83, ""end_span"": 99, ""type"": ""Cell""}, {""token"": ""VPF"", ""start_span"": 118, ""end_span"": 121, ""type"": ""Gene_or_gene_product""}, {""token"": ""vasculature"", ""start_span"": 163, ""end_span"": 174, ""type"": ""Multi""}, {""token"": ""human"", ""start_span"": 183, ""end_span"": 188, ""type"": ""Organism""}, {""token"": ""tumors"", ""start_span"": 189, ""end_span"": 195, ""type"": ""Cancer""}]"
He noted that wounds, like tumors, secrete VPF, causing blood vessels to leak plasma fibrinogen, which stimulates blood vessel growth and provides a matrix on which they can spread.	"wounds	14	20	Pathological_formation"	"tumors	27	33	Cancer"	"VPF	43	46	Gene_or_gene_product"	"blood vessels	56	69	Multi"	"plasma	78	84	Organism_substance"	"fibrinogen	85	95	Gene_or_gene_product"	"blood vessel	114	126	Multi"	"[{""token"": ""wounds"", ""start_span"": 14, ""end_span"": 20, ""type"": ""Pathological_formation""}, {""token"": ""tumors"", ""start_span"": 27, ""end_span"": 33, ""type"": ""Cancer""}, {""token"": ""VPF"", ""start_span"": 43, ""end_span"": 46, ""type"": ""Gene_or_gene_product""}, {""token"": ""blood vessels"", ""start_span"": 56, ""end_span"": 69, ""type"": ""Multi""}, {""token"": ""plasma"", ""start_span"": 78, ""end_span"": 84, ""type"": ""Organism_substance""}, {""token"": ""fibrinogen"", ""start_span"": 85, ""end_span"": 95, ""type"": ""Gene_or_gene_product""}, {""token"": ""blood vessel"", ""start_span"": 114, ""end_span"": 126, ""type"": ""Multi""}]"
Unlike wounds, however, that turn off VPF production after healing, tumors did not turn off their VPF production and instead continued to make large amounts of VPF, allowing malignant cells to continue to induce new blood vessels and so to grow and spread.	"wounds	7	13	Pathological_formation"	"VPF	38	41	Gene_or_gene_product"	"tumors	68	74	Cancer"	"VPF	98	101	Gene_or_gene_product"	"VPF	160	163	Gene_or_gene_product"	"malignant cells	174	189	Cell"	"blood vessels	216	229	Multi"	"[{""token"": ""wounds"", ""start_span"": 7, ""end_span"": 13, ""type"": ""Pathological_formation""}, {""token"": ""VPF"", ""start_span"": 38, ""end_span"": 41, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumors"", ""start_span"": 68, ""end_span"": 74, ""type"": ""Cancer""}, {""token"": ""VPF"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Gene_or_gene_product""}, {""token"": ""VPF"", ""start_span"": 160, ""end_span"": 163, ""type"": ""Gene_or_gene_product""}, {""token"": ""malignant cells"", ""start_span"": 174, ""end_span"": 189, ""type"": ""Cell""}, {""token"": ""blood vessels"", ""start_span"": 216, ""end_span"": 229, ""type"": ""Multi""}]"
In our study, MOG was shown to specifically inhibit the growth of human leukemia cell lines and primary acute myeloid leukemia ( AML) blasts via induction of apoptosis, with the evidence of mitochondrial DeltaPsim loss, reactive oxygen species production, caspases activation and nuclear fragmentation.	"MOG	14	17	Chemical"	"human	66	71	Organism"	"leukemia cell lines	72	91	Cell"	"mitochondrial	190	203	Cellular_component"	"reactive oxygen species	220	243	Chemical"	"caspases	256	264	Gene_or_gene_product"	"nuclear	280	287	Cellular_component"	"[{""token"": ""MOG"", ""start_span"": 14, ""end_span"": 17, ""type"": ""Chemical""}, {""token"": ""human"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Organism""}, {""token"": ""leukemia cell lines"", ""start_span"": 72, ""end_span"": 91, ""type"": ""Cell""}, {""token"": ""mitochondrial"", ""start_span"": 190, ""end_span"": 203, ""type"": ""Cellular_component""}, {""token"": ""reactive oxygen species"", ""start_span"": 220, ""end_span"": 243, ""type"": ""Chemical""}, {""token"": ""caspases"", ""start_span"": 256, ""end_span"": 264, ""type"": ""Gene_or_gene_product""}, {""token"": ""nuclear"", ""start_span"": 280, ""end_span"": 287, ""type"": ""Cellular_component""}]"
Furthermore, it was showed that GSH depletion induced by MOG rendered some leukemia cell lines more sensitive to arsenic trioxide ( As2O3), doxorubicin or cisplatin.	"GSH	32	35	Chemical"	"MOG	57	60	Chemical"	"some leukemia cell lines	70	94	Cell"	"arsenic trioxide	113	129	Chemical"	"As2O3	132	137	Chemical"	"doxorubicin	140	151	Chemical"	"cisplatin	155	164	Chemical"	"[{""token"": ""GSH"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Chemical""}, {""token"": ""MOG"", ""start_span"": 57, ""end_span"": 60, ""type"": ""Chemical""}, {""token"": ""some leukemia cell lines"", ""start_span"": 70, ""end_span"": 94, ""type"": ""Cell""}, {""token"": ""arsenic trioxide"", ""start_span"": 113, ""end_span"": 129, ""type"": ""Chemical""}, {""token"": ""As2O3"", ""start_span"": 132, ""end_span"": 137, ""type"": ""Chemical""}, {""token"": ""doxorubicin"", ""start_span"": 140, ""end_span"": 151, ""type"": ""Chemical""}, {""token"": ""cisplatin"", ""start_span"": 155, ""end_span"": 164, ""type"": ""Chemical""}]"
Surprisingly, analysis of K5CDK4 and K5CDK2 transgenic mouse embryos showed CDK4 and CDK2 expression not only in the expected tissues, but also in the adenohypophysis.	"K5CDK4	26	32	Gene_or_gene_product"	"K5CDK2	37	43	Gene_or_gene_product"	"embryos	61	68	Developing_anatomical_structure"	"CDK4	76	80	Gene_or_gene_product"	"CDK2	85	89	Gene_or_gene_product"	"tissues	126	133	Tissue"	"adenohypophysis	151	166	Organ"	"[{""token"": ""K5CDK4"", ""start_span"": 26, ""end_span"": 32, ""type"": ""Gene_or_gene_product""}, {""token"": ""K5CDK2"", ""start_span"": 37, ""end_span"": 43, ""type"": ""Gene_or_gene_product""}, {""token"": ""embryos"", ""start_span"": 61, ""end_span"": 68, ""type"": ""Developing_anatomical_structure""}, {""token"": ""CDK4"", ""start_span"": 76, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""CDK2"", ""start_span"": 85, ""end_span"": 89, ""type"": ""Gene_or_gene_product""}, {""token"": ""tissues"", ""start_span"": 126, ""end_span"": 133, ""type"": ""Tissue""}, {""token"": ""adenohypophysis"", ""start_span"": 151, ""end_span"": 166, ""type"": ""Organ""}]"
DESIGN: Paraffin - embedded sections of 37 breast carcinomas were immunostained for survivin, bcl - 2, bcl - x, and bax.	"Paraffin	8	16	Chemical"	"sections	28	36	Cancer"	"breast carcinomas	43	60	Cancer"	"survivin	84	92	Gene_or_gene_product"	"bcl - 2	94	101	Gene_or_gene_product"	"bcl - x	103	110	Gene_or_gene_product"	"bax	116	119	Gene_or_gene_product"	"[{""token"": ""Paraffin"", ""start_span"": 8, ""end_span"": 16, ""type"": ""Chemical""}, {""token"": ""sections"", ""start_span"": 28, ""end_span"": 36, ""type"": ""Cancer""}, {""token"": ""breast carcinomas"", ""start_span"": 43, ""end_span"": 60, ""type"": ""Cancer""}, {""token"": ""survivin"", ""start_span"": 84, ""end_span"": 92, ""type"": ""Gene_or_gene_product""}, {""token"": ""bcl - 2"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Gene_or_gene_product""}, {""token"": ""bcl - x"", ""start_span"": 103, ""end_span"": 110, ""type"": ""Gene_or_gene_product""}, {""token"": ""bax"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Gene_or_gene_product""}]"
Transfection of SiHa cervical cancer cells with a plasmid expressing the TSP - 1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe combined immunodeficiency ( SCID) mice, which was accompanied by a decrease in tumor vascularization and lower expressions of alpha - SMA and desmin than those in the vector controls.	"SiHa cervical cancer cells	16	42	Cell"	"TSP - 1	73	80	Gene_or_gene_product"	"tumor	156	161	Cancer"	"mice	213	217	Organism"	"tumor	258	263	Cancer"	"alpha - SMA	305	316	Gene_or_gene_product"	"desmin	321	327	Gene_or_gene_product"	"[{""token"": ""SiHa cervical cancer cells"", ""start_span"": 16, ""end_span"": 42, ""type"": ""Cell""}, {""token"": ""TSP - 1"", ""start_span"": 73, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor"", ""start_span"": 156, ""end_span"": 161, ""type"": ""Cancer""}, {""token"": ""mice"", ""start_span"": 213, ""end_span"": 217, ""type"": ""Organism""}, {""token"": ""tumor"", ""start_span"": 258, ""end_span"": 263, ""type"": ""Cancer""}, {""token"": ""alpha - SMA"", ""start_span"": 305, ""end_span"": 316, ""type"": ""Gene_or_gene_product""}, {""token"": ""desmin"", ""start_span"": 321, ""end_span"": 327, ""type"": ""Gene_or_gene_product""}]"
Transforming growth factor - beta ( TGF - beta), a major factor in the activation of fibroblasts, increased alpha - SMA and desmin expression and the ability of cell migration and invasion in NIH3T3 cells.	"Transforming growth factor - beta	0	33	Gene_or_gene_product"	"TGF - beta	36	46	Gene_or_gene_product"	"fibroblasts	85	96	Cell"	"alpha - SMA	108	119	Gene_or_gene_product"	"desmin	124	130	Gene_or_gene_product"	"cell	161	165	Cell"	"NIH3T3 cells	192	204	Cell"	"[{""token"": ""Transforming growth factor - beta"", ""start_span"": 0, ""end_span"": 33, ""type"": ""Gene_or_gene_product""}, {""token"": ""TGF - beta"", ""start_span"": 36, ""end_span"": 46, ""type"": ""Gene_or_gene_product""}, {""token"": ""fibroblasts"", ""start_span"": 85, ""end_span"": 96, ""type"": ""Cell""}, {""token"": ""alpha - SMA"", ""start_span"": 108, ""end_span"": 119, ""type"": ""Gene_or_gene_product""}, {""token"": ""desmin"", ""start_span"": 124, ""end_span"": 130, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 161, ""end_span"": 165, ""type"": ""Cell""}, {""token"": ""NIH3T3 cells"", ""start_span"": 192, ""end_span"": 204, ""type"": ""Cell""}]"
Here, we show that a portion of laminin - 332, termed G45, which is proteolytically removed and absent in normal tissues, is prominently expressed in most human SCC tumors and plays an important role in human SCC tumorigenesis.	"laminin - 332	32	45	Gene_or_gene_product"	"G45	54	57	Gene_or_gene_product"	"normal tissues	106	120	Tissue"	"human	155	160	Organism"	"SCC tumors	161	171	Cancer"	"human	203	208	Organism"	"SCC	209	212	Cancer"	"[{""token"": ""laminin - 332"", ""start_span"": 32, ""end_span"": 45, ""type"": ""Gene_or_gene_product""}, {""token"": ""G45"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""normal tissues"", ""start_span"": 106, ""end_span"": 120, ""type"": ""Tissue""}, {""token"": ""human"", ""start_span"": 155, ""end_span"": 160, ""type"": ""Organism""}, {""token"": ""SCC tumors"", ""start_span"": 161, ""end_span"": 171, ""type"": ""Cancer""}, {""token"": ""human"", ""start_span"": 203, ""end_span"": 208, ""type"": ""Organism""}, {""token"": ""SCC"", ""start_span"": 209, ""end_span"": 212, ""type"": ""Cancer""}]"
After SCC transformation, the absence of G45 domain in DeltaG45 cells was associated with deficient extracellular signal - regulated kinase and phosphotidylinositol 3 - kinase ( PI3K) pathway activation, impaired invasion, deficient metalloproteinase activity, and absent tumorgenicity in vivo.	"SCC	6	9	Cancer"	"G45	41	44	Gene_or_gene_product"	"DeltaG45	55	63	Gene_or_gene_product"	"extracellular signal - regulated kinase	100	139	Gene_or_gene_product"	"phosphotidylinositol 3 - kinase	144	175	Gene_or_gene_product"	"PI3K	178	182	Gene_or_gene_product"	"metalloproteinase	233	250	Gene_or_gene_product"	"[{""token"": ""SCC"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Cancer""}, {""token"": ""G45"", ""start_span"": 41, ""end_span"": 44, ""type"": ""Gene_or_gene_product""}, {""token"": ""DeltaG45"", ""start_span"": 55, ""end_span"": 63, ""type"": ""Gene_or_gene_product""}, {""token"": ""extracellular signal - regulated kinase"", ""start_span"": 100, ""end_span"": 139, ""type"": ""Gene_or_gene_product""}, {""token"": ""phosphotidylinositol 3 - kinase"", ""start_span"": 144, ""end_span"": 175, ""type"": ""Gene_or_gene_product""}, {""token"": ""PI3K"", ""start_span"": 178, ""end_span"": 182, ""type"": ""Gene_or_gene_product""}, {""token"": ""metalloproteinase"", ""start_span"": 233, ""end_span"": 250, ""type"": ""Gene_or_gene_product""}]"
The reference intervals for serum IL - 8 and urine IL - 8 corrected by creatinine ( Cr) were 15. 9 - 430. 3 pg / mL and 0. 0 - 28. 4 pg / mg Cr, respectively.	"serum	28	33	Organism_substance"	"IL - 8	34	40	Gene_or_gene_product"	"urine	45	50	Organism_substance"	"IL - 8	51	57	Gene_or_gene_product"	"creatinine	71	81	Chemical"	"Cr	84	86	Chemical"	"Cr	141	143	Chemical"	"[{""token"": ""serum"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Organism_substance""}, {""token"": ""IL - 8"", ""start_span"": 34, ""end_span"": 40, ""type"": ""Gene_or_gene_product""}, {""token"": ""urine"", ""start_span"": 45, ""end_span"": 50, ""type"": ""Organism_substance""}, {""token"": ""IL - 8"", ""start_span"": 51, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""creatinine"", ""start_span"": 71, ""end_span"": 81, ""type"": ""Chemical""}, {""token"": ""Cr"", ""start_span"": 84, ""end_span"": 86, ""type"": ""Chemical""}, {""token"": ""Cr"", ""start_span"": 141, ""end_span"": 143, ""type"": ""Chemical""}]"
During normal skin function, p53 in the keratinocyte is a transducer of the skin tanning signal and an essential component of what is effectively a keratinocyte - melanocyte signaling cycle that regulates skin pigmentation.	"skin	14	18	Organ"	"p53	29	32	Gene_or_gene_product"	"keratinocyte	40	52	Cell"	"skin	76	80	Organ"	"keratinocyte	148	160	Cell"	"melanocyte	163	173	Cell"	"skin	205	209	Organ"	"[{""token"": ""skin"", ""start_span"": 14, ""end_span"": 18, ""type"": ""Organ""}, {""token"": ""p53"", ""start_span"": 29, ""end_span"": 32, ""type"": ""Gene_or_gene_product""}, {""token"": ""keratinocyte"", ""start_span"": 40, ""end_span"": 52, ""type"": ""Cell""}, {""token"": ""skin"", ""start_span"": 76, ""end_span"": 80, ""type"": ""Organ""}, {""token"": ""keratinocyte"", ""start_span"": 148, ""end_span"": 160, ""type"": ""Cell""}, {""token"": ""melanocyte"", ""start_span"": 163, ""end_span"": 173, ""type"": ""Cell""}, {""token"": ""skin"", ""start_span"": 205, ""end_span"": 209, ""type"": ""Organ""}]"
Here, we investigate S727 phosphorylation of Stat3 and its subsequent effects in prostate cancer development, independent of Y705 phosphorylation, using mutated Stat3 in the human prostate cancer cell line LNCaP.	"S727	21	25	Amino_acid"	"Stat3	45	50	Gene_or_gene_product"	"prostate cancer	81	96	Cancer"	"Y705	125	129	Amino_acid"	"Stat3	161	166	Gene_or_gene_product"	"human	174	179	Organism"	"prostate cancer cell line LNCaP	180	211	Cell"	"[{""token"": ""S727"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Amino_acid""}, {""token"": ""Stat3"", ""start_span"": 45, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""prostate cancer"", ""start_span"": 81, ""end_span"": 96, ""type"": ""Cancer""}, {""token"": ""Y705"", ""start_span"": 125, ""end_span"": 129, ""type"": ""Amino_acid""}, {""token"": ""Stat3"", ""start_span"": 161, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 174, ""end_span"": 179, ""type"": ""Organism""}, {""token"": ""prostate cancer cell line LNCaP"", ""start_span"": 180, ""end_span"": 211, ""type"": ""Cell""}]"
The knockdown of robo4 abrogated the chemotactic response of endothelial cells to serum but enhanced a chemokinetic response to Slit2, while robo1 knockdown cells do not display chemotactic response to serum or VEGF.	"robo4	17	22	Gene_or_gene_product"	"endothelial cells	61	78	Cell"	"serum	82	87	Organism_substance"	"Slit2	128	133	Gene_or_gene_product"	"robo1	141	146	Gene_or_gene_product"	"serum	202	207	Organism_substance"	"VEGF	211	215	Gene_or_gene_product"	"[{""token"": ""robo4"", ""start_span"": 17, ""end_span"": 22, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial cells"", ""start_span"": 61, ""end_span"": 78, ""type"": ""Cell""}, {""token"": ""serum"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Organism_substance""}, {""token"": ""Slit2"", ""start_span"": 128, ""end_span"": 133, ""type"": ""Gene_or_gene_product""}, {""token"": ""robo1"", ""start_span"": 141, ""end_span"": 146, ""type"": ""Gene_or_gene_product""}, {""token"": ""serum"", ""start_span"": 202, ""end_span"": 207, ""type"": ""Organism_substance""}, {""token"": ""VEGF"", ""start_span"": 211, ""end_span"": 215, ""type"": ""Gene_or_gene_product""}]"
The aim of this study was to compare the effects of PRP and platelet - poor plasma ( PPP) on healing of critical - size bone defects. Bilateral full - thickness, critical - size bone defects were created in the parietal bones of 32 rabbits, which had been studied in 4 groups.	"PRP	52	55	Organism_substance"	"platelet - poor plasma	60	82	Organism_substance"	"PPP	85	88	Organism_substance"	"bone	120	124	Organ"	"bone	178	182	Organ"	"parietal bones	211	225	Organ"	"rabbits	232	239	Organism"	"[{""token"": ""PRP"", ""start_span"": 52, ""end_span"": 55, ""type"": ""Organism_substance""}, {""token"": ""platelet - poor plasma"", ""start_span"": 60, ""end_span"": 82, ""type"": ""Organism_substance""}, {""token"": ""PPP"", ""start_span"": 85, ""end_span"": 88, ""type"": ""Organism_substance""}, {""token"": ""bone"", ""start_span"": 120, ""end_span"": 124, ""type"": ""Organ""}, {""token"": ""bone"", ""start_span"": 178, ""end_span"": 182, ""type"": ""Organ""}, {""token"": ""parietal bones"", ""start_span"": 211, ""end_span"": 225, ""type"": ""Organ""}, {""token"": ""rabbits"", ""start_span"": 232, ""end_span"": 239, ""type"": ""Organism""}]"
Here, we established lymph node metastasis models by injecting overexpressing VEGF - D Lewis lung carcinoma cells into C57BL / 6 mice to explore the effect of honokiol on tumor - associated lymphangiogenesis and related lymph node metastasis.	"lymph node	21	31	Multi"	"VEGF - D	78	86	Gene_or_gene_product"	"Lewis lung carcinoma cells	87	113	Cell"	"C57BL / 6 mice	119	133	Organism"	"honokiol	159	167	Chemical"	"tumor	171	176	Cancer"	"lymph node	220	230	Multi"	"[{""token"": ""lymph node"", ""start_span"": 21, ""end_span"": 31, ""type"": ""Multi""}, {""token"": ""VEGF - D"", ""start_span"": 78, ""end_span"": 86, ""type"": ""Gene_or_gene_product""}, {""token"": ""Lewis lung carcinoma cells"", ""start_span"": 87, ""end_span"": 113, ""type"": ""Cell""}, {""token"": ""C57BL / 6 mice"", ""start_span"": 119, ""end_span"": 133, ""type"": ""Organism""}, {""token"": ""honokiol"", ""start_span"": 159, ""end_span"": 167, ""type"": ""Chemical""}, {""token"": ""tumor"", ""start_span"": 171, ""end_span"": 176, ""type"": ""Cancer""}, {""token"": ""lymph node"", ""start_span"": 220, ""end_span"": 230, ""type"": ""Multi""}]"
In in vitro study, honokiol inhibited VEGF - D - induced survival, proliferation and tube - formation of both human umbilical vein endothelial cells ( HUVECs) and lymphatic vascular endothelial cells ( HLECs).	"honokiol	19	27	Chemical"	"VEGF - D	38	46	Gene_or_gene_product"	"tube -	85	91	Tissue"	"human umbilical vein endothelial cells	110	148	Cell"	"HUVECs	151	157	Cell"	"lymphatic vascular endothelial cells	163	199	Cell"	"HLECs	202	207	Cell"	"[{""token"": ""honokiol"", ""start_span"": 19, ""end_span"": 27, ""type"": ""Chemical""}, {""token"": ""VEGF - D"", ""start_span"": 38, ""end_span"": 46, ""type"": ""Gene_or_gene_product""}, {""token"": ""tube -"", ""start_span"": 85, ""end_span"": 91, ""type"": ""Tissue""}, {""token"": ""human umbilical vein endothelial cells"", ""start_span"": 110, ""end_span"": 148, ""type"": ""Cell""}, {""token"": ""HUVECs"", ""start_span"": 151, ""end_span"": 157, ""type"": ""Cell""}, {""token"": ""lymphatic vascular endothelial cells"", ""start_span"": 163, ""end_span"": 199, ""type"": ""Cell""}, {""token"": ""HLECs"", ""start_span"": 202, ""end_span"": 207, ""type"": ""Cell""}]"
To verify that P18 acts in the same manner as PEDF, we used immunohistochemistry to measure PEDF targets, vascular endothelial growth factor receptor 2, and CD95 ligand expression in P18 - treated vasculature.	"P18	15	18	Gene_or_gene_product"	"PEDF	46	50	Gene_or_gene_product"	"PEDF targets	92	104	Gene_or_gene_product"	"vascular endothelial growth factor receptor 2	106	151	Gene_or_gene_product"	"CD95 ligand	157	168	Gene_or_gene_product"	"P18	183	186	Gene_or_gene_product"	"vasculature	197	208	Multi"	"[{""token"": ""P18"", ""start_span"": 15, ""end_span"": 18, ""type"": ""Gene_or_gene_product""}, {""token"": ""PEDF"", ""start_span"": 46, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""PEDF targets"", ""start_span"": 92, ""end_span"": 104, ""type"": ""Gene_or_gene_product""}, {""token"": ""vascular endothelial growth factor receptor 2"", ""start_span"": 106, ""end_span"": 151, ""type"": ""Gene_or_gene_product""}, {""token"": ""CD95 ligand"", ""start_span"": 157, ""end_span"": 168, ""type"": ""Gene_or_gene_product""}, {""token"": ""P18"", ""start_span"": 183, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""vasculature"", ""start_span"": 197, ""end_span"": 208, ""type"": ""Multi""}]"
In tumor studies, P18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 34 - mer; in the renal cell carcinoma, P18 strongly decreased angiogenesis and halted the progression of established tumors.	"tumor	3	8	Cancer"	"P18	18	21	Gene_or_gene_product"	"prostate cancer	88	103	Cancer"	"parental 34 - mer	109	126	Gene_or_gene_product"	"renal cell carcinoma	135	155	Cancer"	"P18	157	160	Gene_or_gene_product"	"tumors	235	241	Cancer"	"[{""token"": ""tumor"", ""start_span"": 3, ""end_span"": 8, ""type"": ""Cancer""}, {""token"": ""P18"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Gene_or_gene_product""}, {""token"": ""prostate cancer"", ""start_span"": 88, ""end_span"": 103, ""type"": ""Cancer""}, {""token"": ""parental 34 - mer"", ""start_span"": 109, ""end_span"": 126, ""type"": ""Gene_or_gene_product""}, {""token"": ""renal cell carcinoma"", ""start_span"": 135, ""end_span"": 155, ""type"": ""Cancer""}, {""token"": ""P18"", ""start_span"": 157, ""end_span"": 160, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumors"", ""start_span"": 235, ""end_span"": 241, ""type"": ""Cancer""}]"
These antivascular actions are due in part to direct effects on endothelial cells, and all MBDs ( both microtubule - stabilizing and microtubule - destabilizing) inhibit endothelial cell proliferation, migration, and tube formation in vitro, actions that are thought to correspond to therapeutic antiangiogenic actions.	"antivascular	6	18	Multi"	"endothelial cells	64	81	Cell"	"MBDs	91	95	Chemical"	"microtubule	103	114	Cellular_component"	"microtubule	133	144	Cellular_component"	"endothelial cell	170	186	Cell"	"tube	217	221	Tissue"	"[{""token"": ""antivascular"", ""start_span"": 6, ""end_span"": 18, ""type"": ""Multi""}, {""token"": ""endothelial cells"", ""start_span"": 64, ""end_span"": 81, ""type"": ""Cell""}, {""token"": ""MBDs"", ""start_span"": 91, ""end_span"": 95, ""type"": ""Chemical""}, {""token"": ""microtubule"", ""start_span"": 103, ""end_span"": 114, ""type"": ""Cellular_component""}, {""token"": ""microtubule"", ""start_span"": 133, ""end_span"": 144, ""type"": ""Cellular_component""}, {""token"": ""endothelial cell"", ""start_span"": 170, ""end_span"": 186, ""type"": ""Cell""}, {""token"": ""tube"", ""start_span"": 217, ""end_span"": 221, ""type"": ""Tissue""}]"
Perlecan was also found to stimulate endothelial cell proliferation in vitro over a period of 6 days in the presence of plasma proteins and fibroblastic growth factor 2 ( FGF - 2), however in the absence of FGF - 2 endothelial cell growth could not be maintained during this period.	"Perlecan	0	8	Gene_or_gene_product"	"endothelial cell	37	53	Cell"	"plasma	120	126	Organism_substance"	"fibroblastic growth factor 2	140	168	Gene_or_gene_product"	"FGF - 2	171	178	Gene_or_gene_product"	"FGF - 2	207	214	Gene_or_gene_product"	"endothelial cell	215	231	Cell"	"[{""token"": ""Perlecan"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial cell"", ""start_span"": 37, ""end_span"": 53, ""type"": ""Cell""}, {""token"": ""plasma"", ""start_span"": 120, ""end_span"": 126, ""type"": ""Organism_substance""}, {""token"": ""fibroblastic growth factor 2"", ""start_span"": 140, ""end_span"": 168, ""type"": ""Gene_or_gene_product""}, {""token"": ""FGF - 2"", ""start_span"": 171, ""end_span"": 178, ""type"": ""Gene_or_gene_product""}, {""token"": ""FGF - 2"", ""start_span"": 207, ""end_span"": 214, ""type"": ""Gene_or_gene_product""}, {""token"": ""endothelial cell"", ""start_span"": 215, ""end_span"": 231, ""type"": ""Cell""}]"
Antiprogestin RU - 486 inhibits the induction of VEGF and TSP - 1 by progestins, suggesting that this effect of progestin is mediated by the progesterone receptor ( PR).	"Antiprogestin RU - 486	0	22	Chemical"	"VEGF	49	53	Gene_or_gene_product"	"TSP - 1	58	65	Gene_or_gene_product"	"progestins	69	79	Chemical"	"progestin	112	121	Chemical"	"progesterone receptor	141	162	Gene_or_gene_product"	"PR	165	167	Gene_or_gene_product"	"[{""token"": ""Antiprogestin RU - 486"", ""start_span"": 0, ""end_span"": 22, ""type"": ""Chemical""}, {""token"": ""VEGF"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Gene_or_gene_product""}, {""token"": ""TSP - 1"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Gene_or_gene_product""}, {""token"": ""progestins"", ""start_span"": 69, ""end_span"": 79, ""type"": ""Chemical""}, {""token"": ""progestin"", ""start_span"": 112, ""end_span"": 121, ""type"": ""Chemical""}, {""token"": ""progesterone receptor"", ""start_span"": 141, ""end_span"": 162, ""type"": ""Gene_or_gene_product""}, {""token"": ""PR"", ""start_span"": 165, ""end_span"": 167, ""type"": ""Gene_or_gene_product""}]"
Reduction of TCF activity in these cells attenuates their ability to form brain and bone metastases in mice, independently of effects on tumor growth in the lungs.	"TCF	13	16	Gene_or_gene_product"	"cells	35	40	Cell"	"brain	74	79	Organ"	"bone	84	88	Organ"	"mice	103	107	Organism"	"tumor	137	142	Cancer"	"lungs	157	162	Organ"	"[{""token"": ""TCF"", ""start_span"": 13, ""end_span"": 16, ""type"": ""Gene_or_gene_product""}, {""token"": ""cells"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Cell""}, {""token"": ""brain"", ""start_span"": 74, ""end_span"": 79, ""type"": ""Organ""}, {""token"": ""bone"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Organ""}, {""token"": ""mice"", ""start_span"": 103, ""end_span"": 107, ""type"": ""Organism""}, {""token"": ""tumor"", ""start_span"": 137, ""end_span"": 142, ""type"": ""Cancer""}, {""token"": ""lungs"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Organ""}]"
Thus, a distinct WNT / TCF signaling program through LEF1 and HOXB9 enhances the competence of lung adenocarcinoma cells to colonize the bones and the brain.	"WNT	17	20	Gene_or_gene_product"	"TCF	23	26	Gene_or_gene_product"	"LEF1	53	57	Gene_or_gene_product"	"HOXB9	62	67	Gene_or_gene_product"	"lung adenocarcinoma cells	95	120	Cell"	"bones	137	142	Organ"	"brain	151	156	Organ"	"[{""token"": ""WNT"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Gene_or_gene_product""}, {""token"": ""TCF"", ""start_span"": 23, ""end_span"": 26, ""type"": ""Gene_or_gene_product""}, {""token"": ""LEF1"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""HOXB9"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""lung adenocarcinoma cells"", ""start_span"": 95, ""end_span"": 120, ""type"": ""Cell""}, {""token"": ""bones"", ""start_span"": 137, ""end_span"": 142, ""type"": ""Organ""}, {""token"": ""brain"", ""start_span"": 151, ""end_span"": 156, ""type"": ""Organ""}]"
Moreover, we demonstrate that this inflammation - driven netrin - 1 up - regulation is causal for colorectal cancer development as interference with netrin - 1 autocrine loop in a mouse model for ulcerative colitis - associated colorectal cancer, while showing no effect on inflammation, inhibits colorectal cancer progression.	"netrin - 1	57	67	Gene_or_gene_product"	"colorectal cancer	98	115	Cancer"	"netrin - 1	149	159	Gene_or_gene_product"	"mouse	180	185	Organism"	"ulcerative	196	206	Pathological_formation"	"colorectal cancer	228	245	Cancer"	"colorectal cancer	297	314	Cancer"	"[{""token"": ""netrin - 1"", ""start_span"": 57, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""colorectal cancer"", ""start_span"": 98, ""end_span"": 115, ""type"": ""Cancer""}, {""token"": ""netrin - 1"", ""start_span"": 149, ""end_span"": 159, ""type"": ""Gene_or_gene_product""}, {""token"": ""mouse"", ""start_span"": 180, ""end_span"": 185, ""type"": ""Organism""}, {""token"": ""ulcerative"", ""start_span"": 196, ""end_span"": 206, ""type"": ""Pathological_formation""}, {""token"": ""colorectal cancer"", ""start_span"": 228, ""end_span"": 245, ""type"": ""Cancer""}, {""token"": ""colorectal cancer"", ""start_span"": 297, ""end_span"": 314, ""type"": ""Cancer""}]"
Gene expression data from bone marrow ( BM), liver, and spleen of mice exposed to a single dose ( 4 h) or seven daily doses of 2 - BE were used to develop a mechanistic model of hemangiosarcoma.	"bone marrow	26	37	Multi"	"BM	40	42	Multi"	"liver	45	50	Organ"	"spleen	56	62	Organ"	"mice	66	70	Organism"	"2 - BE	127	133	Chemical"	"hemangiosarcoma	178	193	Cancer"	"[{""token"": ""bone marrow"", ""start_span"": 26, ""end_span"": 37, ""type"": ""Multi""}, {""token"": ""BM"", ""start_span"": 40, ""end_span"": 42, ""type"": ""Multi""}, {""token"": ""liver"", ""start_span"": 45, ""end_span"": 50, ""type"": ""Organ""}, {""token"": ""spleen"", ""start_span"": 56, ""end_span"": 62, ""type"": ""Organ""}, {""token"": ""mice"", ""start_span"": 66, ""end_span"": 70, ""type"": ""Organism""}, {""token"": ""2 - BE"", ""start_span"": 127, ""end_span"": 133, ""type"": ""Chemical""}, {""token"": ""hemangiosarcoma"", ""start_span"": 178, ""end_span"": 193, ""type"": ""Cancer""}]"
In addition, the model supports local tissue hypoxia in the liver and spleen, coupled with increased erythropoeitin signaling and erythropoiesis in the spleen and BM, and suppression of mechanisms that contribute to genomic stability, events that could be contributing factors to hemangiosarcoma formation.	"tissue	38	44	Tissue"	"liver	60	65	Organ"	"spleen	70	76	Organ"	"erythropoeitin	101	115	Gene_or_gene_product"	"spleen	152	158	Organ"	"BM	163	165	Multi"	"hemangiosarcoma	280	295	Cancer"	"[{""token"": ""tissue"", ""start_span"": 38, ""end_span"": 44, ""type"": ""Tissue""}, {""token"": ""liver"", ""start_span"": 60, ""end_span"": 65, ""type"": ""Organ""}, {""token"": ""spleen"", ""start_span"": 70, ""end_span"": 76, ""type"": ""Organ""}, {""token"": ""erythropoeitin"", ""start_span"": 101, ""end_span"": 115, ""type"": ""Gene_or_gene_product""}, {""token"": ""spleen"", ""start_span"": 152, ""end_span"": 158, ""type"": ""Organ""}, {""token"": ""BM"", ""start_span"": 163, ""end_span"": 165, ""type"": ""Multi""}, {""token"": ""hemangiosarcoma"", ""start_span"": 280, ""end_span"": 295, ""type"": ""Cancer""}]"
ICAM - 3 enhances the migratory and invasive potential of human non - small cell lung cancer cells by inducing MMP - 2 and MMP - 9 via Akt and CREB.	"ICAM - 3	0	8	Gene_or_gene_product"	"human	58	63	Organism"	"non - small cell lung cancer cells	64	98	Cell"	"MMP - 2	111	118	Gene_or_gene_product"	"MMP - 9	123	130	Gene_or_gene_product"	"Akt	135	138	Gene_or_gene_product"	"CREB	143	147	Gene_or_gene_product"	"[{""token"": ""ICAM - 3"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Organism""}, {""token"": ""non - small cell lung cancer cells"", ""start_span"": 64, ""end_span"": 98, ""type"": ""Cell""}, {""token"": ""MMP - 2"", ""start_span"": 111, ""end_span"": 118, ""type"": ""Gene_or_gene_product""}, {""token"": ""MMP - 9"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Gene_or_gene_product""}, {""token"": ""Akt"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Gene_or_gene_product""}, {""token"": ""CREB"", ""start_span"": 143, ""end_span"": 147, ""type"": ""Gene_or_gene_product""}]"
Knocking down p24delta1 in insulinoma cell lines, which also resulted in the concomitant knock - down of other family members, impaired glucose - stimulated insulin secretion, decreased total cellular insulin content and reduced proinsulin biosynthesis.	"p24delta1	14	23	Gene_or_gene_product"	"insulinoma cell lines	27	48	Cell"	"glucose	136	143	Chemical"	"insulin	157	164	Gene_or_gene_product"	"cellular	192	200	Cell"	"insulin	201	208	Gene_or_gene_product"	"proinsulin	229	239	Gene_or_gene_product"	"[{""token"": ""p24delta1"", ""start_span"": 14, ""end_span"": 23, ""type"": ""Gene_or_gene_product""}, {""token"": ""insulinoma cell lines"", ""start_span"": 27, ""end_span"": 48, ""type"": ""Cell""}, {""token"": ""glucose"", ""start_span"": 136, ""end_span"": 143, ""type"": ""Chemical""}, {""token"": ""insulin"", ""start_span"": 157, ""end_span"": 164, ""type"": ""Gene_or_gene_product""}, {""token"": ""cellular"", ""start_span"": 192, ""end_span"": 200, ""type"": ""Cell""}, {""token"": ""insulin"", ""start_span"": 201, ""end_span"": 208, ""type"": ""Gene_or_gene_product""}, {""token"": ""proinsulin"", ""start_span"": 229, ""end_span"": 239, ""type"": ""Gene_or_gene_product""}]"
BACKGROUND: The aim of this study was to investigate not only the intratumoral and peritumoral lymphatic vessel density ( ILD and PLD) but also the expression of vascular endothelial growth factors ( VEGFs) and to test their correlation with regional lymph nodal metastases in papillary thyroid microcarcinoma ( PTMC).	"intratumoral	66	78	Cancer"	"peritumoral lymphatic vessel	83	111	Multi"	"vascular endothelial growth factors	162	197	Gene_or_gene_product"	"VEGFs	200	205	Gene_or_gene_product"	"lymph nodal	251	262	Multi"	"papillary thyroid microcarcinoma	277	309	Cancer"	"PTMC	312	316	Cancer"	"[{""token"": ""intratumoral"", ""start_span"": 66, ""end_span"": 78, ""type"": ""Cancer""}, {""token"": ""peritumoral lymphatic vessel"", ""start_span"": 83, ""end_span"": 111, ""type"": ""Multi""}, {""token"": ""vascular endothelial growth factors"", ""start_span"": 162, ""end_span"": 197, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGFs"", ""start_span"": 200, ""end_span"": 205, ""type"": ""Gene_or_gene_product""}, {""token"": ""lymph nodal"", ""start_span"": 251, ""end_span"": 262, ""type"": ""Multi""}, {""token"": ""papillary thyroid microcarcinoma"", ""start_span"": 277, ""end_span"": 309, ""type"": ""Cancer""}, {""token"": ""PTMC"", ""start_span"": 312, ""end_span"": 316, ""type"": ""Cancer""}]"
Multikinase inhibitor sorafenib inhibits proliferation and angiogenesis of tumors by suppressing the Raf / MEK / ERK signaling pathway and VEGF receptor tyrosine kinase.	"sorafenib	22	31	Chemical"	"tumors	75	81	Cancer"	"Raf	101	104	Gene_or_gene_product"	"MEK	107	110	Gene_or_gene_product"	"ERK	113	116	Gene_or_gene_product"	"VEGF receptor	139	152	Gene_or_gene_product"	"tyrosine	153	161	Amino_acid"	"[{""token"": ""sorafenib"", ""start_span"": 22, ""end_span"": 31, ""type"": ""Chemical""}, {""token"": ""tumors"", ""start_span"": 75, ""end_span"": 81, ""type"": ""Cancer""}, {""token"": ""Raf"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Gene_or_gene_product""}, {""token"": ""MEK"", ""start_span"": 107, ""end_span"": 110, ""type"": ""Gene_or_gene_product""}, {""token"": ""ERK"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGF receptor"", ""start_span"": 139, ""end_span"": 152, ""type"": ""Gene_or_gene_product""}, {""token"": ""tyrosine"", ""start_span"": 153, ""end_span"": 161, ""type"": ""Amino_acid""}]"
Sorafenib treatment led to accumulation of autophagosomes as evidenced by conversion from LC3 - I to LC3 - II observed by immunoblot in Huh7, HLF and PLC / PRF / 5 cells.	"Sorafenib	0	9	Chemical"	"autophagosomes	43	57	Cellular_component"	"LC3 - I	90	97	Gene_or_gene_product"	"LC3 - II	101	109	Gene_or_gene_product"	"Huh7	136	140	Cell"	"HLF	142	145	Cell"	"PLC / PRF / 5 cells	150	169	Cell"	"[{""token"": ""Sorafenib"", ""start_span"": 0, ""end_span"": 9, ""type"": ""Chemical""}, {""token"": ""autophagosomes"", ""start_span"": 43, ""end_span"": 57, ""type"": ""Cellular_component""}, {""token"": ""LC3 - I"", ""start_span"": 90, ""end_span"": 97, ""type"": ""Gene_or_gene_product""}, {""token"": ""LC3 - II"", ""start_span"": 101, ""end_span"": 109, ""type"": ""Gene_or_gene_product""}, {""token"": ""Huh7"", ""start_span"": 136, ""end_span"": 140, ""type"": ""Cell""}, {""token"": ""HLF"", ""start_span"": 142, ""end_span"": 145, ""type"": ""Cell""}, {""token"": ""PLC / PRF / 5 cells"", ""start_span"": 150, ""end_span"": 169, ""type"": ""Cell""}]"
This induction was due to activation of autophagic flux, as there was further increase in LC3 - II expression upon treatment with lysosomal inhibitors, clear decline of the autophagy substrate p62, and an mRFP - GFP - LC3 fluorescence change in sorafenib - treated hepatoma cells.	"LC3 - II	90	98	Gene_or_gene_product"	"p62	193	196	Gene_or_gene_product"	"mRFP	205	209	Gene_or_gene_product"	"GFP	212	215	Gene_or_gene_product"	"LC3	218	221	Gene_or_gene_product"	"sorafenib	245	254	Chemical"	"hepatoma cells	265	279	Cell"	"[{""token"": ""LC3 - II"", ""start_span"": 90, ""end_span"": 98, ""type"": ""Gene_or_gene_product""}, {""token"": ""p62"", ""start_span"": 193, ""end_span"": 196, ""type"": ""Gene_or_gene_product""}, {""token"": ""mRFP"", ""start_span"": 205, ""end_span"": 209, ""type"": ""Gene_or_gene_product""}, {""token"": ""GFP"", ""start_span"": 212, ""end_span"": 215, ""type"": ""Gene_or_gene_product""}, {""token"": ""LC3"", ""start_span"": 218, ""end_span"": 221, ""type"": ""Gene_or_gene_product""}, {""token"": ""sorafenib"", ""start_span"": 245, ""end_span"": 254, ""type"": ""Chemical""}, {""token"": ""hepatoma cells"", ""start_span"": 265, ""end_span"": 279, ""type"": ""Cell""}]"
Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally - induced glioma ( RG1 2. 2) of rat brain.	"blood	24	29	Organism_substance"	"glucose	36	43	Chemical"	"glucose	75	82	Chemical"	"ATP	87	90	Chemical"	"glioma	127	133	Cancer"	"rat	149	152	Organism"	"brain	153	158	Organ"	"[{""token"": ""blood"", ""start_span"": 24, ""end_span"": 29, ""type"": ""Organism_substance""}, {""token"": ""glucose"", ""start_span"": 36, ""end_span"": 43, ""type"": ""Chemical""}, {""token"": ""glucose"", ""start_span"": 75, ""end_span"": 82, ""type"": ""Chemical""}, {""token"": ""ATP"", ""start_span"": 87, ""end_span"": 90, ""type"": ""Chemical""}, {""token"": ""glioma"", ""start_span"": 127, ""end_span"": 133, ""type"": ""Cancer""}, {""token"": ""rat"", ""start_span"": 149, ""end_span"": 152, ""type"": ""Organism""}, {""token"": ""brain"", ""start_span"": 153, ""end_span"": 158, ""type"": ""Organ""}]"
In experimental RG1 2. 2 glioma of rat brain, local blood flow, glucose utilization, protein synthesis, glucose and ATP content were measured by means of triple tracer autoradiography and bioluminescence technique, respectively, to determine hemodynamic and metabolic thresholds for local tumor energy failure.	"rat	35	38	Organism"	"brain	39	44	Organ"	"blood	52	57	Organism_substance"	"glucose	64	71	Chemical"	"glucose	104	111	Chemical"	"ATP	116	119	Chemical"	"tumor	289	294	Cancer"	"[{""token"": ""rat"", ""start_span"": 35, ""end_span"": 38, ""type"": ""Organism""}, {""token"": ""brain"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Organ""}, {""token"": ""blood"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Organism_substance""}, {""token"": ""glucose"", ""start_span"": 64, ""end_span"": 71, ""type"": ""Chemical""}, {""token"": ""glucose"", ""start_span"": 104, ""end_span"": 111, ""type"": ""Chemical""}, {""token"": ""ATP"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Chemical""}, {""token"": ""tumor"", ""start_span"": 289, ""end_span"": 294, ""type"": ""Cancer""}]"
Because AR - ARD1 interaction facilitated the AR binding to its targeted promoters for gene transcription, we propose that ARD1 functions as a unique AR regulator and forms a positive feedback loop for AR - dependent prostate tumorigenesis.	"AR	8	10	Gene_or_gene_product"	"ARD1	13	17	Gene_or_gene_product"	"AR	46	48	Gene_or_gene_product"	"ARD1	123	127	Gene_or_gene_product"	"AR	150	152	Gene_or_gene_product"	"AR	202	204	Gene_or_gene_product"	"prostate	217	225	Organ"	"[{""token"": ""AR"", ""start_span"": 8, ""end_span"": 10, ""type"": ""Gene_or_gene_product""}, {""token"": ""ARD1"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Gene_or_gene_product""}, {""token"": ""AR"", ""start_span"": 46, ""end_span"": 48, ""type"": ""Gene_or_gene_product""}, {""token"": ""ARD1"", ""start_span"": 123, ""end_span"": 127, ""type"": ""Gene_or_gene_product""}, {""token"": ""AR"", ""start_span"": 150, ""end_span"": 152, ""type"": ""Gene_or_gene_product""}, {""token"": ""AR"", ""start_span"": 202, ""end_span"": 204, ""type"": ""Gene_or_gene_product""}, {""token"": ""prostate"", ""start_span"": 217, ""end_span"": 225, ""type"": ""Organ""}]"
However, in Apc mutation - induced intestinal tumors, inactivation of Hes1 alone was sufficient for reducing tumor cell proliferation and inducing differentiation of tumor cells into all types of intestinal epithelial cells, but without affecting the homeostasis of normal crypts owing to genetic redundancy.	"Apc	12	15	Gene_or_gene_product"	"intestinal tumors	35	52	Cancer"	"Hes1	70	74	Gene_or_gene_product"	"tumor cell	109	119	Cell"	"tumor cells	166	177	Cell"	"intestinal epithelial cells	196	223	Cell"	"crypts	273	279	Multi"	"[{""token"": ""Apc"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Gene_or_gene_product""}, {""token"": ""intestinal tumors"", ""start_span"": 35, ""end_span"": 52, ""type"": ""Cancer""}, {""token"": ""Hes1"", ""start_span"": 70, ""end_span"": 74, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor cell"", ""start_span"": 109, ""end_span"": 119, ""type"": ""Cell""}, {""token"": ""tumor cells"", ""start_span"": 166, ""end_span"": 177, ""type"": ""Cell""}, {""token"": ""intestinal epithelial cells"", ""start_span"": 196, ""end_span"": 223, ""type"": ""Cell""}, {""token"": ""crypts"", ""start_span"": 273, ""end_span"": 279, ""type"": ""Multi""}]"
Both B and T lymphocytes diversify their antigen receptors through RAG1 / 2 mediated recombination, but B cells undergo two additional processes - - somatic hypermutation ( SHM) and class - switch recombination ( CSR), both initiated by activation - induced cytidine deaminase ( AID).	"B	0	1	Cell"	"T lymphocytes	11	24	Cell"	"RAG1	67	71	Gene_or_gene_product"	"2	74	75	Gene_or_gene_product"	"B cells	104	111	Cell"	"activation - induced cytidine deaminase	237	276	Gene_or_gene_product"	"AID	279	282	Gene_or_gene_product"	"[{""token"": ""B"", ""start_span"": 0, ""end_span"": 1, ""type"": ""Cell""}, {""token"": ""T lymphocytes"", ""start_span"": 11, ""end_span"": 24, ""type"": ""Cell""}, {""token"": ""RAG1"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Gene_or_gene_product""}, {""token"": ""2"", ""start_span"": 74, ""end_span"": 75, ""type"": ""Gene_or_gene_product""}, {""token"": ""B cells"", ""start_span"": 104, ""end_span"": 111, ""type"": ""Cell""}, {""token"": ""activation - induced cytidine deaminase"", ""start_span"": 237, ""end_span"": 276, ""type"": ""Gene_or_gene_product""}, {""token"": ""AID"", ""start_span"": 279, ""end_span"": 282, ""type"": ""Gene_or_gene_product""}]"
Transformation of BHK hamster fibroblasts by an env - strain of Rous sarcoma virus ( RSV) leads to the appearance at the cell surface of a virus - induced nonvirion antigen ( VCSA), specific for transformation, whose expression is controlled by the transforming src gene.	"BHK hamster fibroblasts	18	41	Cell"	"Rous sarcoma virus	64	82	Organism"	"RSV	85	88	Organism"	"cell surface	121	133	Cellular_component"	"virus - induced nonvirion antigen	139	172	Gene_or_gene_product"	"VCSA	175	179	Gene_or_gene_product"	"src	262	265	Gene_or_gene_product"	"[{""token"": ""BHK hamster fibroblasts"", ""start_span"": 18, ""end_span"": 41, ""type"": ""Cell""}, {""token"": ""Rous sarcoma virus"", ""start_span"": 64, ""end_span"": 82, ""type"": ""Organism""}, {""token"": ""RSV"", ""start_span"": 85, ""end_span"": 88, ""type"": ""Organism""}, {""token"": ""cell surface"", ""start_span"": 121, ""end_span"": 133, ""type"": ""Cellular_component""}, {""token"": ""virus - induced nonvirion antigen"", ""start_span"": 139, ""end_span"": 172, ""type"": ""Gene_or_gene_product""}, {""token"": ""VCSA"", ""start_span"": 175, ""end_span"": 179, ""type"": ""Gene_or_gene_product""}, {""token"": ""src"", ""start_span"": 262, ""end_span"": 265, ""type"": ""Gene_or_gene_product""}]"
This observation indicates that VCSA expression at the cell surface is likely to be the result of the interaction between the viral src gene product pp60src with host cell gene ( s) or gene product ( s), rather than the simple expression of this molecule at the cell surface.	"VCSA	32	36	Gene_or_gene_product"	"cell surface	55	67	Cellular_component"	"viral	126	131	Organism"	"src	132	135	Gene_or_gene_product"	"pp60src	149	156	Gene_or_gene_product"	"cell	167	171	Cell"	"cell surface	262	274	Cellular_component"	"[{""token"": ""VCSA"", ""start_span"": 32, ""end_span"": 36, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell surface"", ""start_span"": 55, ""end_span"": 67, ""type"": ""Cellular_component""}, {""token"": ""viral"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Organism""}, {""token"": ""src"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Gene_or_gene_product""}, {""token"": ""pp60src"", ""start_span"": 149, ""end_span"": 156, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 167, ""end_span"": 171, ""type"": ""Cell""}, {""token"": ""cell surface"", ""start_span"": 262, ""end_span"": 274, ""type"": ""Cellular_component""}]"
Treatment of murine pulmonary capillary endothelial cells with HAH - cortisol at 10 ( - 5) M ( with respect to cortisol) suppressed their DNA synthesis by 50% and inhibited their migration into wounded areas of confluent monolayers.	"murine	13	19	Organism"	"pulmonary capillary endothelial cells	20	57	Cell"	"HAH - cortisol	63	77	Chemical"	"cortisol	111	119	Chemical"	"DNA	138	141	Cellular_component"	"wounded areas	194	207	Pathological_formation"	"monolayers	221	231	Cell"	"[{""token"": ""murine"", ""start_span"": 13, ""end_span"": 19, ""type"": ""Organism""}, {""token"": ""pulmonary capillary endothelial cells"", ""start_span"": 20, ""end_span"": 57, ""type"": ""Cell""}, {""token"": ""HAH - cortisol"", ""start_span"": 63, ""end_span"": 77, ""type"": ""Chemical""}, {""token"": ""cortisol"", ""start_span"": 111, ""end_span"": 119, ""type"": ""Chemical""}, {""token"": ""DNA"", ""start_span"": 138, ""end_span"": 141, ""type"": ""Cellular_component""}, {""token"": ""wounded areas"", ""start_span"": 194, ""end_span"": 207, ""type"": ""Pathological_formation""}, {""token"": ""monolayers"", ""start_span"": 221, ""end_span"": 231, ""type"": ""Cell""}]"
Human K562 cells, which express PHGPX, but not GPX, were also more sensitive to t - BuOOH in the Se - deficient ( K. Se ( -)) than Se - satisfied ( K. Se ( +)) condition.	"Human	0	5	Organism"	"K562 cells	6	16	Cell"	"PHGPX	32	37	Gene_or_gene_product"	"GPX	47	50	Gene_or_gene_product"	"t - BuOOH	80	89	Chemical"	"Se	97	99	Chemical"	"Se	117	119	Chemical"	"[{""token"": ""Human"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Organism""}, {""token"": ""K562 cells"", ""start_span"": 6, ""end_span"": 16, ""type"": ""Cell""}, {""token"": ""PHGPX"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Gene_or_gene_product""}, {""token"": ""GPX"", ""start_span"": 47, ""end_span"": 50, ""type"": ""Gene_or_gene_product""}, {""token"": ""t - BuOOH"", ""start_span"": 80, ""end_span"": 89, ""type"": ""Chemical""}, {""token"": ""Se"", ""start_span"": 97, ""end_span"": 99, ""type"": ""Chemical""}, {""token"": ""Se"", ""start_span"": 117, ""end_span"": 119, ""type"": ""Chemical""}]"
Appearance of tumorous phenotypes in goldfish erythrophores transfected with ras, src, and myc oncogenes and spontaneous differentiation of the transformants in vitro.	"tumorous	14	22	Cancer"	"goldfish	37	45	Organism"	"erythrophores	46	59	Cell"	"ras	77	80	Gene_or_gene_product"	"src	82	85	Gene_or_gene_product"	"myc	91	94	Gene_or_gene_product"	"transformants	144	157	Cell"	"[{""token"": ""tumorous"", ""start_span"": 14, ""end_span"": 22, ""type"": ""Cancer""}, {""token"": ""goldfish"", ""start_span"": 37, ""end_span"": 45, ""type"": ""Organism""}, {""token"": ""erythrophores"", ""start_span"": 46, ""end_span"": 59, ""type"": ""Cell""}, {""token"": ""ras"", ""start_span"": 77, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""src"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Gene_or_gene_product""}, {""token"": ""myc"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Gene_or_gene_product""}, {""token"": ""transformants"", ""start_span"": 144, ""end_span"": 157, ""type"": ""Cell""}]"
Patterns of X - chromosome inactivation, mutations in the K - ras gene, mutations or allelic loss of the p53 gene, or human papillomavirus detection were identical in both endometrial and ovarian lesions in three of the cases suggesting that those three cases represented single primary tumors with metastases.	"X - chromosome	12	26	Cellular_component"	"K - ras	58	65	Gene_or_gene_product"	"p53	105	108	Gene_or_gene_product"	"human papillomavirus	118	138	Organism"	"endometrial	172	183	Pathological_formation"	"ovarian lesions	188	203	Pathological_formation"	"primary tumors	279	293	Cancer"	"[{""token"": ""X - chromosome"", ""start_span"": 12, ""end_span"": 26, ""type"": ""Cellular_component""}, {""token"": ""K - ras"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Gene_or_gene_product""}, {""token"": ""p53"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Gene_or_gene_product""}, {""token"": ""human papillomavirus"", ""start_span"": 118, ""end_span"": 138, ""type"": ""Organism""}, {""token"": ""endometrial"", ""start_span"": 172, ""end_span"": 183, ""type"": ""Pathological_formation""}, {""token"": ""ovarian lesions"", ""start_span"": 188, ""end_span"": 203, ""type"": ""Pathological_formation""}, {""token"": ""primary tumors"", ""start_span"": 279, ""end_span"": 293, ""type"": ""Cancer""}]"
The high - oncogenic - risk HPV types associated with invasive cervical cancer produce two oncoproteins, designated E6 and E7, which interact with endogenous cell cycle regulatory proteins, including p53 and Rb.	"HPV	28	31	Organism"	"cervical cancer	63	78	Cancer"	"E6	116	118	Gene_or_gene_product"	"E7	123	125	Gene_or_gene_product"	"cell	158	162	Cell"	"p53	200	203	Gene_or_gene_product"	"Rb	208	210	Gene_or_gene_product"	"[{""token"": ""HPV"", ""start_span"": 28, ""end_span"": 31, ""type"": ""Organism""}, {""token"": ""cervical cancer"", ""start_span"": 63, ""end_span"": 78, ""type"": ""Cancer""}, {""token"": ""E6"", ""start_span"": 116, ""end_span"": 118, ""type"": ""Gene_or_gene_product""}, {""token"": ""E7"", ""start_span"": 123, ""end_span"": 125, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 158, ""end_span"": 162, ""type"": ""Cell""}, {""token"": ""p53"", ""start_span"": 200, ""end_span"": 203, ""type"": ""Gene_or_gene_product""}, {""token"": ""Rb"", ""start_span"": 208, ""end_span"": 210, ""type"": ""Gene_or_gene_product""}]"
Treatment of NIH 3T3 cells with the PKC inhibitor staurosporine, the tyrosine kinase inhibitor herbimycin A, and the AA metabolism inhibitor quinacrine induces apoptotic cell death.	"NIH 3T3 cells	13	26	Cell"	"PKC	36	39	Gene_or_gene_product"	"staurosporine	50	63	Chemical"	"herbimycin A	95	107	Chemical"	"AA	117	119	Chemical"	"quinacrine	141	151	Chemical"	"cell	170	174	Cell"	"[{""token"": ""NIH 3T3 cells"", ""start_span"": 13, ""end_span"": 26, ""type"": ""Cell""}, {""token"": ""PKC"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Gene_or_gene_product""}, {""token"": ""staurosporine"", ""start_span"": 50, ""end_span"": 63, ""type"": ""Chemical""}, {""token"": ""herbimycin A"", ""start_span"": 95, ""end_span"": 107, ""type"": ""Chemical""}, {""token"": ""AA"", ""start_span"": 117, ""end_span"": 119, ""type"": ""Chemical""}, {""token"": ""quinacrine"", ""start_span"": 141, ""end_span"": 151, ""type"": ""Chemical""}, {""token"": ""cell"", ""start_span"": 170, ""end_span"": 174, ""type"": ""Cell""}]"
The present studies examine whether lymphocyte stimulation via cells engineered to secrete GM - CSF or IL - 2 decreases hepatic tumor growth, and whether stimulation of both macrophages and lymphocytes is more effective than either individually.	"lymphocyte	36	46	Cell"	"cells	63	68	Cell"	"GM - CSF	91	99	Gene_or_gene_product"	"IL - 2	103	109	Gene_or_gene_product"	"hepatic tumor	120	133	Cancer"	"macrophages	174	185	Cell"	"lymphocytes	190	201	Cell"	"[{""token"": ""lymphocyte"", ""start_span"": 36, ""end_span"": 46, ""type"": ""Cell""}, {""token"": ""cells"", ""start_span"": 63, ""end_span"": 68, ""type"": ""Cell""}, {""token"": ""GM - CSF"", ""start_span"": 91, ""end_span"": 99, ""type"": ""Gene_or_gene_product""}, {""token"": ""IL - 2"", ""start_span"": 103, ""end_span"": 109, ""type"": ""Gene_or_gene_product""}, {""token"": ""hepatic tumor"", ""start_span"": 120, ""end_span"": 133, ""type"": ""Cancer""}, {""token"": ""macrophages"", ""start_span"": 174, ""end_span"": 185, ""type"": ""Cell""}, {""token"": ""lymphocytes"", ""start_span"": 190, ""end_span"": 201, ""type"": ""Cell""}]"
Upon initiation of angiogenesis with basic fibroblast growth factor ( bFGF) on the chick chorioallantoic membrane ( CAM), endothelial cell mitogen - activated protein ( MAP) kinase ( ERK) activity was detected as early as 5 min yet was sustained for at least 20 h.	"basic fibroblast growth factor	37	67	Gene_or_gene_product"	"bFGF	70	74	Gene_or_gene_product"	"chick	83	88	Organism"	"chorioallantoic membrane	89	113	Multi"	"CAM	116	119	Multi"	"endothelial cell	122	138	Cell"	"ERK	183	186	Gene_or_gene_product"	"[{""token"": ""basic fibroblast growth factor"", ""start_span"": 37, ""end_span"": 67, ""type"": ""Gene_or_gene_product""}, {""token"": ""bFGF"", ""start_span"": 70, ""end_span"": 74, ""type"": ""Gene_or_gene_product""}, {""token"": ""chick"", ""start_span"": 83, ""end_span"": 88, ""type"": ""Organism""}, {""token"": ""chorioallantoic membrane"", ""start_span"": 89, ""end_span"": 113, ""type"": ""Multi""}, {""token"": ""CAM"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Multi""}, {""token"": ""endothelial cell"", ""start_span"": 122, ""end_span"": 138, ""type"": ""Cell""}, {""token"": ""ERK"", ""start_span"": 183, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}]"
Inhibition of MAP kinase kinase ( MEK) during this sustained alphavbeta3 - dependent ERK signal blocked the formation of new blood vessels while not influencing preexisting blood vessels on the CAM.	"MAP kinase kinase	14	31	Gene_or_gene_product"	"MEK	34	37	Gene_or_gene_product"	"alphavbeta3	61	72	Gene_or_gene_product"	"ERK	85	88	Gene_or_gene_product"	"blood vessels	125	138	Multi"	"blood vessels	173	186	Multi"	"CAM	194	197	Multi"	"[{""token"": ""MAP kinase kinase"", ""start_span"": 14, ""end_span"": 31, ""type"": ""Gene_or_gene_product""}, {""token"": ""MEK"", ""start_span"": 34, ""end_span"": 37, ""type"": ""Gene_or_gene_product""}, {""token"": ""alphavbeta3"", ""start_span"": 61, ""end_span"": 72, ""type"": ""Gene_or_gene_product""}, {""token"": ""ERK"", ""start_span"": 85, ""end_span"": 88, ""type"": ""Gene_or_gene_product""}, {""token"": ""blood vessels"", ""start_span"": 125, ""end_span"": 138, ""type"": ""Multi""}, {""token"": ""blood vessels"", ""start_span"": 173, ""end_span"": 186, ""type"": ""Multi""}, {""token"": ""CAM"", ""start_span"": 194, ""end_span"": 197, ""type"": ""Multi""}]"
